Nuclease-free editing of b cells through class-switch recombination
Engineered nucleic acids with targeted homology arms enable precise editing of B cells' immunoglobulin loci, addressing the inefficiencies in existing methods and enhancing therapeutic antibody production by facilitating precise immunoglobulin engineering through class-switch recombination.
Patent Information
- Application Number
- PCT/US2024/037396
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-07-10
- Filing Date
- 2024-07-10
- Publication Date
- 2025-01-16
AI Technical Summary
Current methods for genetically modifying B cells to engineer immunoglobulins lack precision and efficiency in editing nucleotide sequences within the immunoglobulin locus, particularly through class-switch recombination, which is essential for therapeutic antibody production.
The use of engineered nucleic acids with specific homology arms that target sequences within or proximal to the immunoglobulin switch regions, combined with homology-directed repair mechanisms, to facilitate precise insertion of heterologous nucleic acids into the immunoglobulin locus, enabling efficient editing of B cells without the need for nucleases like CRISPR.
This approach allows for precise and efficient editing of B cells, enhancing the production of engineered immunoglobulins with desired properties, such as improved antigen specificity and immune response efficacy, while avoiding off-target effects.
Smart Images

Figure US2024037396_16012025_PF_FP_ABST
Abstract
Description
[0001]UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ NUCLEASE-FREE EDITING OF B CELLS THROUGH CLASS-SWITCH RECOMBINATION ^ RELATED APPLICATIONS The application claims the benefit under 35 U.S.C. 119(e) of U.S. ProvisionalApplication number 63 / 512,883 filed July 10, 2023, which is incorporated by reference in its entirety. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT This invention was made with government support under Grant No. DA056771 awarded by the National Institutes of Health. The government has certain rights in the invention. REFERENCE TO AN ELECTRONIC SEQUENCE LISTING The contents of the electronic sequence listing (U119770221WO00-SEQ-PRW.xml; Size: 194,361 bytes; and Date of Creation: July 9, 2024) is herein incorporated by reference in its entirety. BACKGROUND B cells participate in immune responses by producing antibodies known as immunoglobulins that identify and neutralize infectious agents by binding to epitopes present on pathogen antigens. B cells are capable of expressing a variety of immunoglobulin isotypes comprising different heavy chain sequences during a process called class-switch recombination. In turn, class-switch recombination produces a suite of immunoglobulins capable of binding to a common antigen present on a pathogen. Genetic modification of B cells to engineer immunoglobulins may be used for therapeutic purposes. SUMMARY UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ Aspects of the present disclosure relate to nucleic acids that can be utilized to edit a nucleotide sequence located in an immunoglobulin locus. In some aspects, the present disclosure relates to a nucleic acid comprising from 5' to 3' a first homology arm, a heterologous nucleic acid, and a second homology arm, wherein at least one of the homology arms comprises homology to: a sequence within an immunoglobulin switch (S) region; a sequence proximal to an immunoglobulin switch (S) region; or a sequence spanning the boundary of an immunoglobulin switch (S) region and a sequence proximal to the immunoglobulin S region. For example, in some aspects, the disclosure relates to a nucleic acid comprising from 5' to 3' a first homology arm, a heterologous nucleic acid, and a second homology arm, wherein at least one of the homology arms comprises homology to a sequence within an active immunoglobulin switch (S) region, a sequence proximal to an active immunoglobulin switch (S) region, or a sequence spanning the boundary of an active immunoglobulin switch (S) region and a sequence proximal to the active immunoglobulin S region. In some embodiments, the sequence proximal to the active immunoglobulin S region comprises a human immunoglobulin heavy chain locus sequence or a mouse immunoglobulin heavy chain locus sequence. In some embodiments, the sequence proximal to the active immunoglobulin S region is upstream of the active immunoglobulin S region. In some embodiments, the sequence proximal to the active immunoglobulin S region is downstream of the active immunogloblin S region. In some embodiments, the active immunoglobulin S region comprises a human active S region or a mouse active S region. In some embodiments, at least one of the homology arms comprises homology to a sequence proximal to the active immunoglobulin S region. In some embodiments, at least one homology arm comprises homology to a sequence within the active immunoglobulin S region. In some embodiments, only one of the homology arms comprises homology to a sequence proximal to the active immunoglobulin S region and the other homology arm comprises homology to sequences within the same active immunoglobulin S region or a different active S region. In some embodiments, both homology arms comprise homology to sequences proximal to the same active immunoglobulin S region. In some embodiments, both homology arms comprise homology to a sequence within the same active immunoglobulin S region or different active immunoglobulin S regions. In some embodiments, one of the homology arms comprises UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ homology to sequences upstream of at least one AID target motif in the active S region, and the other homology arm comprises homology to sequences downstream of at least one AID target motif in the same or different active immunoglobulin S region. In some embodiments, the nucleic acid comprises at least one regulatory sequence. In some embodiments, the at least one regulatory sequence comprises a promoter, an enhancer, or both. In some embodiments, the nucleic acid is vector. In some embodiments, the nucleic acid further comprises a first adeno-associated virus (AAV) inverted terminal repeat (ITR) located 5' of the first homology arm and a second AAV ITR located 3' of the second homology arm. In some embodiments, the present dislcosure relates to a recombinant adeno-associated virus (rAAV) particle comprising any of the nucleic acids described herein. Other aspects of the present disclosure relate to an engineered immunoglobulin produced or obtained from genetically modified B cells described herein. Meanwhile, other aspects of the present dislcosure relate to methods of genetically modifying cells (e.g., B cells) and methods of treating a subject. Additionally, the present dislcosure further relates to compositions (e.g., pharmaceutical compositions) and kits comprising nucleic acids, rAAV particles, cells, and / or engineered immunoglobulins described herein. BRIEF DESCRIPTION OF THE DRAWINGS FIGs.1A-1I show non-limiting examples of engineered template nucleic acid designs and how class-switch recombination facilitates precise insertion of heterologous nucleic acids. FIG.1A shows three non-limiting examples of an engineered template nucleic acid design for HDR-directed editing at the mouse immunoglobulin (Ig) heavy chain locus during CSR. FIG. 1B shows three non-limiting examples of an engineered template nucleic acid design for HDR- directed editing at the mouse Ig heavy chain locus during intra-S recombination. FIG.1C shows outcomes of CSR at the mouse Ig heavy chain locus. FIG.1D shows the designs of engineered template nucleic acids. The top schematic shows the genomic Sµ and Sα regions before CSR. The bottom schematics show two examples of engineered template nucleic acids. Triangles indicate sites of Sµ-Sµ and Sµ-Sα junctions found in class-switched murine CH12-F3 cells observed in analyses described herein. FIG.1E shows CSR efficiency of CH12-F3 cells after incubation with anti-CD40, TGF-β1, and IL-4 and quantifications of the same (right bar graph). UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ N =3; error bars indicate SEM. FIG.1F shows gel electrophoresis analysis of PCR products generated by amplification of an edited Sµ region comprising integrated heterologous nucleic acid. FIG.1G shows a second replicate of the experiment described in FIG.1F. FIG.1H shows gel electrophoresis analysis of PCR products generated by amplification of an edited Sα region comprising integrated heterologous nucleic acid. FIG.1I shows a second replicate of the experiment described in FIG.1H. In FIGs.1F-1I, primers are indicated as arrows.; triangles show PCR products; controls comprised samples treated with CSR-inducing conditions in the absence of engineered template nucleic acid and samples contacted with engineered template nucleic acid without CSR-inducing treamtent. FIGs.2A-2E show insertion of exogenous peptides encoded by a heterologous nucleic acid into an antibody elbow region FIG.2A shows murine engineered IgG1 comprising its “elbow,” indicated by the shaded region marked with an arrow, linking VH and CH domains (left panel), human Fab comprising leukocyte immunoglobulin-like receptor B1 domains 3 and 4 (LILRB1-d3d4) at the “elbow” bound to Plasmodium falciparum surface peptides (RIFIN, repetitive interspersed families of polypeptides) (middle panel), and the ALFA tag (right panel). FIG.2B shows flow cytometry analyses of membrane-bound OKT-3 engineered antibodies (IgM, IgG1, and IgA), comprising ALFA-tag at the “elbows”, expression in 293F cells. FIG.2C shows a summary of the results from FIG.2B. Error bars indicate SEM. FIG.2D shows a similar analysis as in FIG.2B wherein human LILRB1-domains 3 and 4 (LILRB1-d3d4) and LILRB1-domain 3 (LILRB1-d3) were introduced at the OKT-3 elbows. FIG.2E shows a summary of results from FIG.2D. For FIGs.2B-2E, Expi293F cells overexpressing the indicated constructs were co-stained with anti-Igκ, soluble human-CD3 (binding surface OKT-3), and anti- ALFA antibodies. Numbers in each flow graph indicate average percentage of double positive cells within the gate (± SEM); N = 3. FIGs.3A-3G show an example of a strategy for integration of heterologous nucleic acids comprising an ALFA tag and human LILRB1 domains at the BCR elbow of CH12-F3 cells. FIG.3A shows examples of engineered template nucleic acids, provided on AAV vectors, used to insert heterologous nucleic acids comprising an ALFA tag and LILRB1-d3d4 into the Sµ region and at Sµ-Sα junctions of mouse Igh locus in CH12-F3 cells. FIG.3B shows examples of heterologous nucleic acids comprising ALFA or LILRB1 sequences. In5, in6, and in7 = introns 5, 6, and 7, respectively, from the human LILRB1 locus; Ex7 and ex8 = exons 7 and 8, UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ respectively, of human LILRB1; triangles indicate splice acceptor (dark shade) and splice donor (light shade) sequences. FIG.3C shows examples of editing strategies for insertion of a heterologous nucleic acid comprising ALFA tag and LILRB1-d3d4 into the Sµ and Sµ-Sα of mouse Igh locus in CH12-F3 cells delivered via an rAAV comprising an engineered template nucleic acid using either CSR- or CRISPR-mediated approaches. BCR with the IgM isotype are indicated in dark shading and with the IgA are indicated in light shading; elbow inserts are in shaded region between regions labeled “VDJ” and “CH”. FIG.3D shows flow cytometry analyses of CSR- and CRISPR-mediated ALFA insertions using ALFA-Sµ and ALFA-Sα engineered template nucleic acids depicted in FIG.3A. Numbers indicate percentage of heterologous nucleic acid comprising ALFA tag inserts determined by the indicated gate are shown in each panel; controls included: cells not treated with CSR-inducing conditions, cells transduced with an irrelevant luciferase-expressing AAV vector (luciferase) and treated with CSR-inducing conditions, and untransduced cells (no AAV) treated with CSR-inducing conditions. FIG.3E shows a summary of results from experiments similar to those shown in FIG.3C. N= 3; error bars show SEM. FIG.3F shows results from a similar analysis described in FIGs.3C-3D wherein engineered template nucleic acids comprising LILRB1-Sµ sequences were used. FIG.3G shows results from a similar analysis described in FIGs.3C-3D wherein engineered template nucleic acids comprising LILRB1-Sα sequences were used. FIGs.4A-4E show insertion of ALFA tag encoded by a heterologous nucleic acid at the BCR elbow of murine primary B cells. FIG.4A shows flow cytometry analyses of CSR in murine primary B cells treated with LPS and IL-4, low-dose LPS (LPSLo), or anti-CD180 antibodies. Numbers indicate percentage of cells class-switched to IgG1 determined by the indicated gate are shown. N=3; errors bars = SEM. FIG.4B shows an example of a strategy for S-region editing in murine primary B cells. FIG.4C shows flow cytometry analyses of efficiencies of ALFA elbow insertion in the presence of indicated cytokine and immune activator treatments. Numbers indicate percentage of ALFA-expressing cells determined by the indicated gate. FIG.4D shows a summary of results from three to five replicates of experiments similar to those in FIG.4C wherein a single CRISPR-mediated editing approach was also included for comparison. Error bars = SEM. FIG.4E shows the isotypes of ALFA+cells treated with LPS and IL-4 or low-dose LPS alone from FIG.4D. N =1. UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ FIGs.5A-5E show patterns of CSR-mediated editing using AAV-expressed engineered template nucleic acids. FIG.5A shows an example of a PCR strategy at the Sµ region and sequences of cloned PCR products. A primer pair (red arrows) amplifies from genomic regions homologous to first and second homology arms of the engineered template nucleic acid. Dashed lines mark the outer edges of homologous regions on reference genomic DNA. Shaded regions located between homology arms indicate heterologous nucleic acid, with the middle shaded region indicating the coding region of the ALFA tag and the flanking shaded regions located between the homology arms indicating the extended splice acceptor and donor regions derived from LILRB1. Schematics below “PCR strategy” show various observed PCR products, grouped by editing outcomes (labeled HDR-1 pattern, ITR-1 pattern, etc.). The number in parentheses beneath the final PCR product indicates microhomology length at this junction. LPS and IL-4 treated IgK+ALFA+primary B cells were isolated by FACS and their genomic DNA was purified for PCR amplification and Sanger sequencing. FIG.5B shows the relative frequencies of the editing patterns described in FIG.5A. PCR products were analyzed by gel electrophoresis and Bands A-C were excised, cloned into a plasmid vector, and sequenced. Bar graph indicates the frequency of each editing pattern observed in sequences obtained from each band. FIG.5C shows an example of a PCR strategy for detection of heterologous nucleic acid integration at the at Sγ1 region. The number in parentheses underneath a PCR product indicates microhomology length at the junction. FIG.5D shows an another example of a PCR strategy similar to FIG.5C. FIG.5E shows gel electrophoresis analysis PCR products and the relative frequencies of the junction patterns generated according to the description of FIGs.5C-5D. The graph indicates frequency from the indicated gel band of each Sγ1 junction pattern described in FIGs.5C-5D. FIGs.6A-6E show the influence of homology arms and splice donors / acceptors on expression of heterologous nucleic acids comprising an ALFA tag. FIG.6A depicts an example of engineered template nucleic acids differing in their homology arms used to edit primary B cells. ALFA-noHA construct did not contain regions homologous to mouse Igh locus. FIG.6B shows CSR-mediated editing efficiencies of ALFA tag insertion using each indicated engineered template nucleic acid shown as bars, and the frequency of each observed isotype is indicated with a pie chart. FIG.6C depicts the design of engineered template nucleic acids used to edit primary murine B cells. The engineered template nucleic acids shown are similar to those shown in FIG.6A except that ALFA- Sγ1 engineered template nucleic acid was replaced with ALFA- UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ Sα engineered template nucleic. FIG.6D shows experiments similar to that in FIG.6B wherein that CH12-F3 cells were edited with the engineered template nucleic acid shown in FIG.6C. FIG.6E shows two splice donor / acceptor pairs compared in primary B cells and CH12-F3 cells. LILRB1 exon 8 indicates splice pairs derived from exon 6 of the LILBR1 gene. Cµ / J4 indicates an acceptor derived from Cµ and a donor derived from J4. Note that all of the preceding experiments used LILRB1 exon 8 splice pair, but, in some embodiments, the Cµ / J4 pair are used. FIGs.7A-7E show non-limiting examples of vectors for engineered template nucleic acid delivery. FIG.7A shows a vector diagram corresponding to the plasmid of SEQ ID NO: 12. FIG.7B shows a vector diagram corresponding to the plasmid of SEQ ID NO: 13. FIG.7C shows a diagram of a vector comprising an engineered repair template nucleic acid corresponding to the plasmid of SEQ ID NO: 28 which was engineered using SEQ ID NO: 12 as a backbone. FIG.7D shows a diagram of a vector comprising an engineered repair template nucleic acid corresponding to the plasmid of SEQ ID NO: 29 which was engineered using SEQ ID NO: 13 as a backbone. FIG.7E shows a vector diagram corresponding to the plasmid of SEQ ID NO: 53. FIGs.8A-8C show non-limiting examples of engineered template nucleic acids for editing an immunoglobulin heavy chain locus. FIGs.9A-9C show non-limiting examples of engineered template nucleic acids that utilize the mu (µ) enhancer (E^) upstream of S^ to express Fc-fusion proteins and other biologics. DETAILED DESCRIPTION The present disclosure relates to compositions and methods for introducing heterologous nucleic acid sequences into the genome of a B cell, or cell population thereof. In some embodiments, the target locus comprises sequences upstream, downstream, and / or within an active switch region. In some embodiments, an engineered template nucleic acid described herein comprise sequence homology to a target locus in B cells and which drive integration of the heterologous nucleic acid into the genome. In some embodiments, the engineered template nucleic acids described herein exploit endogenously induced DSBs in active switch region(s) (S region(s)). In some embodiments, engineered template nucleic acids described herein are designed such that editing may be UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ achieved through CSR (e.g., recombination between two S regions), such as recombination between S^ and S^1(see, e.g., FIG.1A). In some embodiments, engineered template nucleic acids described herein are designed such that editing may be achieved through intra-S recombination (e.g., editing within one S region), such as recombation within S^ (see, e.g., FIG 1B). However, in other embodiments, the engineered template nucleic acids described herein can be utilized in combination with a CRISPR / Cas system described herein to edit a sequence located in a target site, such as a sequence located in an immunoglobulin locus. In some embodiments, one or more engineered template nucleic acids for homology-directed repair (HDR) described herein are introduced into B cells under conditions that promote HDR. In some embodiments, conditions that promote HDR include conditions under which a double strand break is generated at the target site (e.g., within an active S region). In some embodiments, methods and compositions described herein are useful to alter antibody coding sequences in a B cell (e.g., to introduce a modified sequence into an antibody encoded at the immunoglobulin locus of a B cell). However, in some embodiments, methods and compositions described herein are useful to introduce other heterologous nucleic acid sequences (e.g., encoding other genes of interest such as therapeutic genes) into a genomic locus (e.g., the immunoglobulin locus) of the immune cell. In some embodiments, one or more nucleic acids described herein (e.g., a template nucleic acid) are delivered in a viral vector (e.g., in an AAV vector). In some embodiments, recombinant adeno-associated viruses (rAAVs) particles are engineered to deliver template nucleic acids for B cell editing as described herein. In some embodiments, an engineered template nucleic acid is delivered by a rAAV particle to a cell. In some embodiments, delivery of an engineered template nucleic acid by an rAAV particle is used for in vivo editing of B cells. In some embodiments, the present disclosure provides for treatment methods and kits using said engineered nucleic acids and rAAV particles and compositions comprising the same. In some embodiments, genetically engineered B cells comprise engineered immunoglobulins (Igs). In some embodiments, VDJ exons upstream of S and CH regions may be replaced with a designer VDJ. In some embodiments, an engineered B cell expressing an immunoadhesin may be generated. In some embodiments, engineered Igs comprise modified immunoadhesins, such as Fc-fusion proteins, and may be used for the treatment and / or prevention of HIV infections. In some embodiments, Fc-fusion proteins include Embrel, CD4-IgG2, and CD4-IgG1. In some UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ embodiments, engineered B cells and Igs may include an LFA3-IgG1 fusion protein or an TNFR-IgG1 fusion protein for the treatment and / or prevention of autoimmune diseases. In some embodiments, engineered Igs comprising a second recognition domain at the elbow region. In some embodiments, engineered Igs may be produced as an alternative to monoclonal antibody therapy. In some embodiments, native antibodies comprising genetically engineered variable domains with user-defined antigen specificity(s) may be generated. However, these disclosures should not be considered limiting. For example, in some embodiments, non-antibody biologics may also be engineered. In some embodiments, the present disclosure also provides engineered template nucleic acids, and rAAVs thereof, for insertion of erythropoietin (EPO) (e.g., EPOR150A-huGYPA variant) for treatment and / or prevention of EPO deficiency chronic disorders. In some embodiments, present disclosure provides engineered template nucleic acids, and rAAVs thereof, kits for genomic insertion of glucagon-like peptide 1 (GLP-1) for diabetes and congestive heart failure. Immunoglobulins and Class-Switch Recombination in B Cells An immunoglobulin (Ig) molecule is an antibody expressed by B cells (also referred to as “B lymphocytes”) and consists of two identical light chains and two identical heavy chains. In both humans and mice (Mus musculus), the Ig heavy chain locus includes a heavy variable region VDJ and a plurality of CHregions respective to each Ig isotype (see, e.g., the Ig sequences described in Tables 1-2). Humans comprise various Ig isotypes including IgM, IgD, IgG3, IgG1, IgA1, IgG2, IgG4, IgE, and IgA2. Mice comprise Ig various isotypes including IgM, IgD, IgG3, IgG1, IgG2b, IgG2a, IgE, and IgA. The Ig isotypes comprise the same light chain structures but differ with respect to their heavy chain constant (CH) regions. In the house mouse (Mus musculus), the Ig heavy chain locus is located on chromosome 12 (location chromosome 12 F2 at 58.0-59.0 cM). A non-limiting example of an M. musculus Ig heavy chain locus is NG_005838.1. The mouse Ig heavy chain locus and the CHregion exons encoded therein are diagrammed in FIG.1C. Briefly, the Cµ exon encodes the CH sequence ofIgM, the C^ exon encodes the CHsequence of IgD, the C^ exon encodes the CHsequence of IgG,the C^ exon encodes the CHsequence of IgE, and the C^ exon encodes the CHsequence of IgA. Additionally, CH exons may be differentially expressed to produce subclasses of Ig isotypes. For example, in mice, the exon C^1 encodes the CH sequence of IgG1, the C^2a exon encodes the CH UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ sequence of IgG2a, the C^2b exon encodes the CH sequence of IgG2b, and the C^3 exon encodes the CHsequence of IgG3. Moreover, the Ig heavy chain locus comprises a plurality of non- coding sequences including introns corresponding to exons encoding CHregions, such as the I^ intron, the I^3 intron, the I^1 intron, the I^2b intron, the I^2^ intron, the I^ intron, and the I^ intron as well as regulatory sequences (e.g., the E^ enhancer, the 3’ regulator region (3’ RR), the 3’ CTCF-binding element (3’ CBE), etc.). Examples of mouse Ig heavy chain locus sequences are described herein (see, e.g., Table 1). In humans, the Ig heavy chain locus is found on chromosome 14 (location 14q32.33) and comprises a plurality of sequences. A non-limiting example of a human Ig heavy chain locus is comprised in GenBank Reference No. NG_001019.6. The human Ig heavy chain locus comprises VDJ exons, the E^ enhancer, the I^ intron, the S^ region, the Cµ exon, the C^ exon, the I^3intron, the S^3region, the C^3exon, the I^1intron, the S^1region, the C^1exon, the I^1intron, the S^1 region, the C^1 exon, the ^13’ regulatory region (3’ RR), I^2 intron, the S^2 region, the C^2 exon, the I^4 intron, the S^4 region, the C^4 exon, the I^ intron, the S^ region, the C^ exon, the I^2intron, the S^2region, C^2exon,,and ^23’ regulatory region (3’ RR). Examples of human Ig heavy chain locus sequences are described herein (see, e.g., Table 2). Accordingly, it should be appreciated that an immunoglobulin heavy chain locus described herein, such as a mouse locus or a human locus, also includes the intronic regions located between the immunoglobulin heavy chain locus regions (e.g., variable regions, switch regions, intervening regions, constant exons, and enhancers) described above. Isotype-specific CH region expression is determined by the germline organization of the heavy chain locus which is regulated by a process called “class-switch recombination (CSR)” (also known as “isotype switching”). CSR mechanisms in mouse and humans have been previously described. See, e.g., disclosures related to CSR mechanisms in: Pan-Hammarström et al. (2007). Class Switch Recombination: A comparison Between Mouse and Human. Advances in Immunology, 93: 1-61; and Saha et al. (2020). Charting a DNA Repair Roadmap for Immunoglobulin Class Switch Recombination. Trends in Biochemical Sciences, 46(3): 184-199. Briefly, CSR is induced mainly in mature proliferative B cells after binding of activator molecules to membrane-bound B cell receptors. CSR can also be induced under specific circumstances in precursor B cells. Therein, the constant region of the heavy chain is changed while retaining the same variable regions providing the antigen-binding fragments. Thus, Ig UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ isotype switching via CSR does not affect antigen specificity. However, Ig isotypes physically interact with different immune effector proteins (e.g., Fc receptors, poly-Ig receptors, and complement factor) and cells (e.g., macrophages, NK cells, and mast cells). Thus, CSR generates B cells expressing different Ig isotypes capable of recruiting different immune effectors in response to a pathogen thereby enhancing the host immune response. Normal CSR involves intrachromosomal deletional recombination events in the Ig heavy chain locus. In general, said deletions link a “donor” sequence (e.g., one comprising the VDJ antibody region) to an “acceptor” sequence (e.g., one comprising a CHsequence), thereby producing a genomic sequence encoding a specific Ig isotype (e.g., see FIG.1C). As used herein, an “acceptor S region” is the switch (S) region that is recombined with an active upstream switch (S) region (a.k.a. “donor S region”) during CSR, wherein the Ig constant exon immediately downstream of the acceptor S region is expressed after CSR. CSR is induced by mutational events in “switch (S) regions” (e.g., the S^ region, the S^3 region, the S^1 region, the S^2b region, the S^2^ region, the S^ region, and the S^ region) which are upstream of CH exons except for C^. The S regions comprise a plurality of G-rich tandem repeats sequences which comprise approximately 20-80 nucleotides in length. Thus, S regions comprise many instances of G-C base pairs which include “activation-induced cytidine deaminase (AID) target motifs.” AID target motifs undergo the initial mutational events that induce CSR. A non-limiting example of an AID target motif is one that comprises, on the 5’ to 3’ strand, a sequence of the structure: 5’ - RGYW - 3’, wherein R = A / G, Y = C / T, and W = A / T. Accordingly, the reverse complementary sequence, on the 3’ to 5’ strand, comprises the structure: 5’ - WRCY - 3’ which comprises the C that AID targets, wherein R = A / G, Y = C / T, and W = A / T. Deamination of C residues in AID target motifs is followed by uracil DNA glycosylase-dependent excision and apurinic / apyrimidinic endonuclease-dependent single-strand nicking events. Said nicking events lead to double-strand break (DSB) formation. Once DSBs are formed, two outcomes are possible: a productive CSR pathway wherein the switch regions recombine (e.g., see FIG.1C wherein Sµ and Sα recombine) and the intervening genomic region is excised; or a non- productive pathway in which the DSBs are repaired, typically within the Sµ region, without recombination with DSBs at one of the other S regions (intra-S recombination). During CSR, AID target motifs are made accessible by structural changes to chromatin. Said structural changes are activated by transcription wherein S region DNA is made accessible. Thus, as used UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ herein, “active S region” refers to heavy chain locus sequences undergoing transcription (e.g., “productive transcription” which may be used herein to refer to transcription resulting in an mRNA that is translated into a polypeptide, or “sterile transcription” which may be used herein to refer to transcription that does not result in synthesis of a polypeptide). Generally, under normal conditions, active S regions are capable of undergoing genomic rearrangements (e.g., through intra-S recombination- or CSR-dependent mechanisms) triggered by deamination of an AID target motif. DNA Repair Mechanisms DSBs are repaired through mechanisms that normally operate in a cell cycle-specific manner. For example, CSR generally occurs during G1 phase of the cell cycle. Therein, end- joining repair mechanisms (e.g., non-homologous end-joining (NHEJ) and alternative end- joining (A-EJ)) are usually more active than homology-directed repair (HDR) mechanisms. During end-joining mechanisms, DSBs are processed by nucleases that degrade genomic sequences surrounding the DSB and the remaining sequences are ligated together. Thus, end- joining mechanisms result in chromosomal deletions. One example of this includes linking a donor S region and an acceptor S region during CSR. CSR does not normally involve homology-directed repair (HDR) which usually occurs during G2phase of the cell cycle. This is because,once in G2, sister chromatids produced during DNA replication in the preceding S phase are available to serve as a template for DSB repair through HDR. The HDR mechanism involves a sequence of enzyme-mediated steps. Briefly, the DSB is processed by endogenous nucleases producing single-stranded overhangs on the damaged chromosome. Strand invasion follows wherein the overhangs transiently hybridize with a template sequence (e.g., provided by a sister chromatid). The template sequence is in close physical proximity to the damaged DNA molecule through protein-protein interactions between DNA-bound complexes (e.g., cohesin). As such, homology between the chromosome comprising the DSB and the undamaged sister chromatid drives the repair efficiency of HDR. Upon strand invasion, repair polymerases extend the single-stranded overhangs of the damaged chromosome using the homologous sequence as a template. DNA repair is complete when gaps in the polymerized strands are filled by endogenous gap polymerases and ligases. As such, HDR can repair DNA without loss of genomic sequences unlike end-joining repair mechanisms. UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ Without wishing to be bound by any particular theory, by providing an exogenous template nucleic acid in the presence of a DSB, HDR frequency may be enhanced relative to end-joining mechanisms. As such, when an exogenous template sequence is provided, HDR can result in substitution, deletion, and / or insertion of nucleotides at user-defined sites bearing DSBs. ^ Targets Aspects of the present disclosure relate to engineered template nucleic acids that promote gene editing outcomes in B cells at a target site. As used herein, “target site” refers to the unmodified genomic DNA comprising target sequences that are homologous to the homology arms of an engineered template nucleic acid and all of the intervening genomic sequences therein and should be interpreted to refer to wild-type sequences of the Ig heavy chain locus unless referred to otherwise. In some embodiments, a target site comprises two “target sequences” that homology arms hybridize to. In some embodiments, during HDR, the target site is edited to comprise sequences encoded by an engineered template nucleic acid. A target site may comprise any sequences within the Ig heavy chain locus (see, e.g., the nucleotide sequences described in Tables 1-2, such as GenBank Reference Nos. NG_005838.1, NG_001019.6, and^NC_000078.7). In some embodiments, the target site is within a mammalian Ig heavy chain locus (e.g., a human Ig heavy chain locus or a mouse Ig heavy chain locus). In some embodiments, the target site is within the human Ig heavy chain locus. In some embodiments, a human Ig heavy chain locus target sequence comprises sequences found in the VDJ exons, the E^ enhancer, the I^ intron, the S^ region, the Cµ exon, the C^ exon, the I^3intron, the S^3region, the C^3exon, the I^1intron, the S^1 region, the C^1 exon, the I^1 intron, the S^1 region, the C^1 exon, the ^13’ regulatory region (3’ RR), I^2intron, the S^2region, the C^2exon, the I^4intron, the S^4region, the C^4exon, the I^ intron, the S^ region, the C^ exon, the I^2intron, the S^2region, C^2exon,,and ^23’ regulatory region (3’ RR), or an intervening genomic sequence thereof. In some embodiments, the target site is within the mouse Ig heavy chain locus. In some embodiments, a mouse Ig heavy chain locus target sequence comprises sequences found in the VDJ exons, the E^ enhancer, the I^ intron, the S^ region, the C^ exon, the C^ exon, the I^3 intron, the S^3 region, the C^3 exon, the I^1 intron, the S^1 region, the C^1 exon, the I^2b intron, the S^2bregion, the C^2bexon, the I^2^intron, the S^2^region, the C^2^exon, the I^ intron, the S^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ region, the C^ exon, the I^ intron, the S^ region, the C^ exon, the 3’ regulatory region (3’ RR), the CTCF binding element (CBE), or an intervening genome sequence thereof. In some embodiments, a target sequence comprises a segment of an S region (e.g., an active S region), a segment of a CH region exon, a segment of an intron in the Ig heavy chain locus, and / or a segment of a regulatory sequence in the Ig heavy chain locus. In some embodiments, a target sequence comprises an S region, a CHregion exon, an Ig heavy chain locus intron, and / or a regulatory sequence of the Ig heavy chain locus. In some embodiments, a target sequence comprises intervening genomic sequences found between an S region and a CHregion exon, an Ig heavy chain locus intron and an S region, or a regulatory sequence of the Ig heavy chain locus and a downstream element (e.g., an intron, S region, CH region exon, etc.). Accordingly, aspects of the present application relate to engineered template nucleic acids (as well as transgenes, vectors, and recombinant adeno-associated virus (rAAV) genomes comprising an engineered template nucleic acid) that comprise at least one homology arm that hybridizes to a target sequence located in and / or proximal to a region of an immunoglobulin heavy chain locus (e.g., an immunoglobulin heavy chain locus located in a genome of a mammalian cell, such as a genome of a human cell, which includes, but is not limited to, B cells). The region can be referred to herein as “active” if the region comprises a sequence which is transcribed, or capable of being transcribed, in, for example, a B cell (e.g., a B cell in the presence of conditions that promote immunoglobulin production). It should, therefore, be appreciated that homology arms can also be described herein as being located in an engineered template nucleic acid (or a transgene, vector, or recombinant adeno-associated virus (rAAV) genome comprising the engineered template nucleic acid), and comprising homology to a target sequence located in and / or proximal to an active region of an immunoglobulin heavy chain locus, but such descriptions do not require that the engineered template nucleic acid is comprised in a cell (e.g., a B cell) unless stated otherwise. In some embodiments, the target site to be edited using the engineered nucleic acids and methods described herein is determined by which S region is active (e.g., an S region that is undergoing transcription, such as productive transcription or sterile transcription) and engineered nucleic acid template design. In some embodiments, an immunoglobulin heavy chain locus comprising an active S region undergoing productive transcription occurs as a result of a transcription event beginning at one or more VDJ exons and continuing through sequences UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ comprising an S region (e.g., an active S^ region or a downstream active S region that has been recombined). In some embodiments, such a transcription event will normally produce an mRNA that will be translated to produce an amino acid sequence. In some embodiments, an immunoglobulin heavy chain locus comprising an active S region undergoing sterile transcription occurs as a result of a transcription event beginning at an immunoglobulin heavy chain locus intron and continuing through its corresponding S region (e.g., transcription starting at the I^1 intron and continuing through the active S^1 region). In some embodiments, such a transcription event will normally not produce an mRNA that will be translated to produce an amno acid sequence. In some embodiments, an immunoglobulin heavy chain locus target site comprising an active S region (e.g., one undergoing productive transcription or sterile transcription) may be induced in response to, for example, a natural process occurring in one or more B cells, contacting one or more B cells with an antigen associated with a pathogen, treatment of one or more B cells with an agent (e.g., a CSR-stimulating agent described herein), the presence of a CRISPR-activator in one or more B cells, and / or the presence of an immunoglobulin heavy chain locus transcription activator in one or more B cells. In some embodiments, said natural process may comprise binding of activator molecules to membrane-bound B cell receptors in proliferative B cells. In some embodiments, said antigen associated with a pathogen may occur as a result of infection and / or vaccination. For example, in some embodiments, CSR can be induced by contacting a B cell with an antigen (e.g., contacted via immunization of a subject with the antigen, such as wherein the antigen promotes T helper cells to produce signals including, but not limited to, cytokines, such as IL-4, IL-21, and CD40 ligands, that induce class- switching) (see, e.g., dislcosures related to induction of class-switching in Roco et al. (2019). Class-Switch Recombination Occurs Infrequently in Germinal Centers. Immunity, 51(2):337- 350). In some embodiments, said treatment with an agent may comprise contacting one or more B cells with one or more cytokines, such as anti-CD40, CD40L, TGF-^1, IL-4, IL-5, IFN^, IL- 10, bacterial lipopolysaccharide (LPS), retinoic acid (RA), B-cell activating factor (BAFF), anti- ^ mAb, and / or anti-CD180. In some embodiments, one or more mouse B cells are contacted with one or more agents described herein (e.g., one agent or two, three, four, five, six, seven, or more than seven agents), such as anti-CD40 (or CD40L) and IL-4 or LPS and IL-4 (e.g., to induce transcription of a region(s) involved in IgG1 production and / or IgE production), RA and IL-4 UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ and TGFb1 and IL-5 and LPS and BAFF (e.g., to induce transcription of a region(s) involved in IgA production), LPS and IFN-^ (e.g., to induce transcription of a region(s) involved in IgG2a production), or LPS (e.g., to induce transcription of a region(s) involved in IgG3 production). In some embodiments, one or more human B cells are contacted with one or more agents described herein (e.g., one agent or two, three, four, five, six, seven, or more than seven agents), such as CD40L and IL-4 and IL-13 (e.g., to induce transcription of a region(s) involved in IgG4 and / or IgE production), CD40L and IL-10 (e.g., to induce transcription of a region(s) involved in IgG1 and / or IgG3 production), or CD40L and IL-10 and TGF-^ (e.g., to induce transcription of a region(s) involved in IgA1 and / or IgA2 production). In some embodiments, said CRISPR- activator may generate an edit in an immunoglobulin heavy chain sequence to make it transcriptionally active (e.g., an edit that introduces a transcriptional regulatory sequence into the immunoglobulin heavy chain sequence) and / or an edit that induces a DSB (e.g., a DSB induced by a Cas protein). Thus, in some embodiments, the target site to be edited using the engineered nucleic acids and methods described herein may occur in a B cell which may either be ex vivo (e.g., a B cell in culture, such as a cultured autologous or allogenic B cell) or in vivo (e.g., in a human subject, such as a human subject in need thereof). Accordingly, in some embodiments, transcription of an S region (an active S region) may induce editing with or without generation of an AID-induced DSB. However, in some embodiments, an active S region comprises one or more AID target motifs which become damaged, such as by AID-mediated deamination, thereby leading to DSBs. In some embodiments, editing methods described herein involve the formation of at least one DSB in a target site comprising a single active S region. One non-limiting example of a mouse target site comprising a single active S region comprises (shown 5’ to 3’): [VDJ]-[I^]-[S^]-[C^]-[C^]-[I^3]-[S^3]-[C^3]-[I^1]-[S^1]-[C^1]-[I^2b]-[S^2b]-[C^2b]-[I^2^]-[S^2^]- [C^2^]-[I^]-[S^]-[C^]-[I^]-[S^]-[C^], wherein underline indicates regions undergoing transcription and bold indicates the active S^ region comprising AID target motifs. In some embodiments, a target site comprises two active S regions. In some embodiments, editing methods described herein involve the formation of more than one DSB in UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ a target site, wherein one DSB is present in each of the active S regions. One non-limiting example of a mouse target site comprising two active S regions comprises (shown 5’ to 3’): [VDJ]-[I^]-[S^]-[C^]-[C^]-[I^3]-[S^3]-[C^3]-[I^1]-[S^1]-[C^1]-[I^2b]-[S^2b]-[C^2b]-[I^2^]-[S^2^]- [C^2^]-[I^]-[S^]-[C^]-[I^]-[S^]-[C^], wherein underline indicates regions undergoing transcription and bold indicates the active S^ and S^ regions comprising AID target motifs. In some embodiments, a target site comprises three, four, five, or more active S regions. In some embodiments, editing methods described herein comprises the introduction of three, four, five, or more DSBs in a target site. Table 1. Examples of Mouse Immunoglobulin Heavy Chain Locus Sequences ^ Table 2. Examples of Human Immunoglobulin Heavy Chain Locus Sequences UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ It should be appreciated that, at least in some embodiments, a B cell can lack at least one sequence located in the Ig heavy chain locus, or a region thereof, described herein. For example, in some embodiments, a B cell may lack at least one S region, at least one intron, and / or at least one C region. In some embodiments, the B cell has been utilized in an editing method described herein, comprises a mutation in the immunoglobulin heavy chain locus (e.g., a deletion of one or more heavy chain locus regions described herein), and / or undergone CSR under non-genetic engineering conditions (e.g., undergone CSR while present in a subject, such as a subject that has been immunized with an antigen or infected with a pathogen), and the at least one S region, the at least one intron, and / or the at least one C region of the Ig heavy chain locus sequence is located between Sµ and the other sequences encoding the Ig of the isotype expressed by the B cell. In some embodiments, the Sµ region, the S region associated with the sequences encoding the expressed Ig isotype, and / or the S region of the heavy chains downstream thereof can be activated in the B cell (e.g., by contacting the B cell with a treatment that stimulates CSR as described herein) and then subjected to Ig heavy chain locus editing conditions as described herein (e.g., contacting with an engineered template nucleic acid) that edit the Ig heavy chain locus. Accordingly, the present disclosure also provides compositions and methods that can be utilized to edit class-switched B cells and B cells that have genetically engineered to lack one or more sequences located in the Ig heavy chain locus. Engineered Nucleic Acids UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ As used herein, an “engineered nucleic acid” sequence may encompass a DNA, RNA, or DNA / RNA hybrid sequence. In some embodiments, engineered nucleic acids are artificially produced. In some embodiments, an engineered nucleic acid may be: (i) amplified in vitro by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; or (iii) synthesized by, for example, chemical synthesis. In some embodiments, an engineered nucleic acid is one which has been manipulated by recombinant DNA techniques well known in the art. For example, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known, or for which polymerase chain reaction (PCR) primer sequences may be designed, is considered engineered. However, a nucleic acid sequence existing in its native state in its natural host is not. In some embodiments, an engineered nucleic acid may be substantially purified but need not be. In some embodiments, nucleic acids may be considered engineered when a non- naturally occurring gene sequence has been generated in a laboratory setting. Such non-naturally occurring gene sequences comprise, in some embodiments, select components derived from one or more sources of genetic information to yield a nucleic acid encoding a protein with unique functions not found in nature. Non-limiting examples of engineered nucleic acids include, single- stranded engineered template nucleic acids, double-stranded engineered template nucleic acids and transgenes, vectors (e.g., plasmids), and recombinant viral genomes thereof. Engineered Template Nucleic Acids In some embodiments, an “engineered template nucleic acid” refers to a nucleic acid that serves as substrate for HDR and promotes integration of a heterologous nucleic acid into a target site (e.g., a target site comprising a sequence located in the immunoglobulin heavy chain locus). In some embodiments, an engineered template nucleic acid comprises from 5' to 3', in relative order, a first homology arm, a heterologous nucleic acid, and a second homology arm. Various engineered nucleic acids (e.g., engineered template nucleic acids and vectors for delivering a template to a cell) are described herein. See, e.g., FIGs.1A-1D, 3A, 5A, 5C, 5D, 6A, 6C, 7C, 7D, 8A-8C, and 9A-9C, and Tables 3-6. In some embodments, an engineered template nucleic acid described herein is approximately 3-5000 nucleotides in length. In some embodiments, an engineered template nucleic acid is approximately 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70- 80, 80-90, 90-100, 100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 900-1000, 1000-1100, 1100-1200, 1200-1300, 1300-1400, 1400-1500, 1500-1600, 1600-1700, UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ 1700-1800, 1800-1900, 1900-2000, 2000-2100, 2100-2200, 2200-2300, 2300-2400, 2400-2500, 2500-2600, 2600-2700, 2700-2800, 2800-2900, 2900-3000, 3000-3100, 3100-3200, 3200-3300, 3300-3400, 3400-3500, 3500-3600, 3600-3700, 3700-3800, 3900-4000, 4000-4100, 4100-4200, 4200-4300, 4300-4400, 4400-4500, 4500-4600, 4600-4700, 4700-4800, 4800-4900, or 4900- 5000 nucleotides long. In some embodiments, an engineered template nucleic acid is approximately 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, or 5000 nucleotides long. In some embodiments, an engineered template nucleic acid is approximately 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 50-60, 55-65, 60-70, 65-75, 70-80, 75-85, 80-90, 85-95, 90- 100, 95-105, 100-120, 110-130, 120-140, 130-150, 140-160, 150-170, 160-180, 170-190, 180- 200, 190-200, 200-300, 250-350, 300-400, 350-450, 400-500, 450-550, 500-600, 550-650, 600- 700, 650-750, 700-900, 800-1000, 900-1000, 950-1000, 1000-1300, 1100-1400, 1200-1500, 1300-1600, 1400-1700, 1500-1800, 1600-1900, 1700-2000, 1800-2100, 1900-2200, 2000-2500, 2100-2600, 2200-2700, 2300-2800, 2400-2900, 2500-3000, 2600-3100, 2700-3200, 2800-3300, 2900-3400, 3000-3000, 3100-3600, 3200-3700, 3300-3800, 3400-3900, 3500-4000, 3600-4100, 3700-4200, 3800-4300, 3900-4400, 4000-4500, 4100-4600, 4200-4700, 4300-4800, 4400-4900, 4500-500, 4600-500, 4700-500, 4800-5000, or 4900-5000 nucleotides long.^ In some embodiments, an engineered template nucleic acid sequence described herein comprises DNA. In some embodiments, an engineered template nucleic acid sequence described herein comprises RNA. In some embodiments, an engineered template nucleic acid sequence described herein comprises a combination of DNA and RNA. In some embodiments, an engineered template nucleic acid described herein comprises double-stranded DNA. In some embodiments, an engineered template nucleic acid described herein comprises single-stranded DNA. In some embodiments, an engineered template nucleic acid described herein comprises double-stranded RNA. In some embodiments, an engineered template nucleic acid described herein comprises single-stranded RNA. In some embodiments, an engineered template nucleic acid described herein comprises a double-stranded nucleic acid, wherein the double-stranded nucleic acid comprises a combination of DNA and RNA nucleotides. In some embodiments, an engineered template nucleic acid described herein comprises a double-stranded nucleic acid (e.g., UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ DNA, RNA, or a combination of DNA / RNA) comprising gaps (e.g., stretches of sequence about, 1, 5, 10, 25, 50, 100 or more nucleotides in length) of single-stranded sequence at any position within the nucleic acid molecule. In some embodiments, an engineered template nucleic acid described herein is linear. In some embodiments, an engineered template nucleic acid described herein is circular. In some embodiments, an engineered template nucleic acid described herein comprises at least one single-stranded nick. In some embodiments, an engineered template nucleic acid described herein comprises at least one modified nucleotide or internucleotide linkage. As used herein, “modified nucleotide” refers to a nucleotide having one or more chemical modifications when compared with a corresponding reference nucleotide (e.g., a nucleotide which is not chemically modified) selected from: an adenine ribonucleotide, a guanine ribonucleotide, a cytosine ribonucleotide, a uracil ribonucleotide, an adenine deoxyribonucleotide, a guanine deoxyribonucleotide, a cytosine deoxyribonucleotide, and a thymidine deoxyribonucleotide. In some embodiments, chemical modifications (e.g., chemical modifications comprised in an engineered template nucleic acid) may be used to endow a double stranded nucleic acid with specific functional characteristics not exhibited by unmodified nucleic acids. Engineered template nucleic acids of the disclosure may be modified to achieve one or more desired properties, such as, for example, improved cellular uptake, improved stability, reduced immunogenicity, improved potency, improved target hybridization, susceptibility to cleavage by endogenous nucleases, etc. In some embodiments, a modified nucleotide can have, for example, one or more chemical modifications in its sugar, nucleobase, and / or phosphate group. Additionally, or alternatively, a modified nucleotide can have one or more chemical moieties conjugated to a corresponding reference nucleotide (e.g., a nucleotide which is not chemically modified). In some embodiments, the modified nucleotide is a 2'-fluoro modified nucleotide, 2'-O-methyl modified nucleotide, or 2'-O-alkyl modified nucleotide, e.g., a 2’O-C12-16 alkyl modified nucleotide. As used herein, the term “alkyl” means saturated linear or branched-chain monovalent hydrocarbon radical, containing the indicated number of carbon atoms. For example, “C12-16 alkyl” means a radical having 12-16 carbon atoms in a linear or branched arrangement. Additional examples of nucleotides comprising modifications to a 2’ carbon of the sugar group include but are not limited to D-ribose, 2'-deoxy, 2’-O-alkyl (including 2’-O-methyl UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ and 2’-O-ethyl), 2’-alkoxy, 2’-amino, 2'-aminoalkoxy, 2’-S-alkyl, 2’-2-O-methoxyethoxy, 2'-O- methoxyethyl, 2’-allyloxy (OCH2CH=CH2), 2’-propargyl, 2’-propyl, ethynyl, ethenyl, propenyl, and cyano and the like. In some embodiments, the 2’-modified nucleotide comprises a 2'-O-4'-C methylene bridge, such as a locked inhibitory nucleic acid (LNA) nucleotide. In some embodiments, the 2^-hydroxyl group is linked to the 3^ or 4^ carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. Other 2’ modifications are found in the art. In some embodiments, the modified nucleotide has a phosphate analog. As used herein, “phosphate analog” means a chemical moiety that mimics the electrostatic and / or steric properties of a phosphate group. In some embodiments, a phosphate analog is positioned at the 5’ terminal nucleotide of an oligonucleotide in place of a 5’-phosphate, which is often susceptible to enzymatic removal. A 5’ phosphate analog can include a phosphatase-resistant linkage. Examples of phosphate analogs include 5’ methylene phosphonate (5’-MP) and 5’-(E)- vinylphosphonate (5’-VP). In some embodiments, the phosphate analog is 5’-VP. In some embodiments, an engineered template nucleic acid described herein may comprise one or more abasic moieties or inverted abasic moieties. As used herein, “abasic moiety” or “apurinic / apyrimidic site” refers to a molecule derived from a nucleotide which comprises a ribose (or deoxyribose) sugar and phosphate bond from which a nitrogenous base (e.g., nucleobase) has been removed by cleaving the glycosidic bond between the ribose (or deoxyribose) sugar and the base. In some embodiments, an engineered template nucleic acid described herein comprises one or more (e.g., 1, 2, 3, 4, 5, or more) modified internucleotide linkages. As used herein, “modified internucleotide linkage” refers to an internucleotide linkage having one or more chemical modifications when compared with a reference internucleotide linkage having a phosphodiester bond. A modified internucleotide linkage can be a non-naturally occurring linkage. In some embodiments, the modified internucleotide linkage is phosphorothioate (PS) linkage. Examples of other modified nucleic acids and modified internucleotide linkages include, but are not limited to, borano-phosphate, alkyl phosphonate inhibitory nucleic acids, peptide inhibitory nucleic acids, and morpholinos. Morpholino backbones are described, for example by Corey and Abrams Genome Biol.2001; 2(5): reviews1015.1–reviews1015.3. Engineered template nucleic acids described herein may, in some embodiments, be contacted with a cell (e.g., a cell in vitro or in vivo) provided in a transgene, vector, and / or UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ recombinant adeno-associated virus (rAAV) described herein. However, in some embodiments, engineered template nucleic acids may be contacted with a cell (e.g., a cell in vitro or in vivo) in a form that is linearized and devoid of any other sequences (e.g., plasmid backbone, rAAV genome-associated sequences, etc.). Sequences corresponding to engineered template nucleic acids and those corresponding to other sequences provided by, for example, a vector can be annotated using methods (e.g., nucleic acid sequence alignments) described herein. In some embodiments, engineered template nucleic acids described herein are operably linked to regulatory sequences described herein which can be used to control stability, expression, and / or degradation of the engineered template nucleic acid in a host cell (e.g., a host cell in vitro or in vivo). Accordingly, in some embodiments, engineered template nucleic acids may be transcribed into an mRNA molecule in a host cell such that the engineered template nucleic acid and / or the corresponding mRNA product arising from transcription may serve as a substrate during CSR or intra-S recombination. In some embodiments, engineered template nucleic acids described herein comprise: a first homology arm; a heterologous nucleic acid; and a second homology arm. In some embodiments, the first and second homology arms comprise sequences which are homologous to sequences in an immunoglobulin heavy chain locus (see, e.g., the nucleotide sequences described in Tables 1-2, such as GenBank Reference Nos. NG_005838.1, NG_001019.6, and^ NC_000078.7). In some embodiments, engineered template nucleic acids comprise: a first homology arm comprising a nucleic acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to any one of the nucleotide sequences set forth in Tables 1-4 (e.g., any one of SEQ ID NOs: 14, 16, 18, 20, or 21) or a reverse complement thereof; a heterologous nucleic acid comprising a nucleic acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to any one of the nucleotide sequences set forth in Tables 3 and 5 (e.g., any one of SEQ ID NOs: 3-4 or 22-25) or a reverse complement thereof; and a second homology arm comprising a nucleic acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to any one of the nucleotide sequences set forth in Tabls 1-4 (e.g., any one of SEQ ID NOs: 15, 17, 19, or 27) or a reverse complement thereof. In some embodiments, engineered template nucleic acids comprise: a first homology arm comprising any one of the nucleic acid sequences set forth in Table 4 (e.g., any one of SEQ ID UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ NOs: 14, 16, 18, 20, or 21) or a reverse complement thereof; a heterologous nucleic acid comprises any one of the nucleic acid sequences st forth in Table 5 (e.g., of any one of SEQ ID NOs: 3-4 or 22-25); and a second homology arm comprising any one of the nucleic acid sequences set forth in Table 4 (e.g.,any one of SEQ ID NOs: 15, 17, 19, or 27) or a reverse complement thereof. In some embodiments, the engineered template nucleic acid comprises a nucleic acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to any one of the sequences set forth in Tables 3-6 (e.g., any one of SEQ ID NOs: 3-4 or 7-29.) or a reverse complement thereof. In some embodiments, the engineered template nucleic acid comprises any one of the nucleic acid sequences set forth in Tables 3-6 (e.g., any one of SEQ ID NOs: 3-4, 7-25, or 27-29). The term “% sequence identity” or “percentage sequence identity” with respect to a reference nucleic acid sequence is defined as the percentage of nucleotides, nucleosides, or nucleobases in a query sequence that are identical with the nucleotides, nucleosides, or nucleobases in the reference nucleic acid sequence, after optimally aligning the sequences and introducing gaps or overhangs, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the means of one of ordinary skill in the art, for instance, using publicly available computer software programs, for example, those described in Current Protocols in Molecular Biology (Ausubel et al., eds., 1987, Supp.30, section 7.7.18, Table 7.7.1), and including, but not limited to, BLAST, BLAST-2, ALIGN, Megalign (DNASTAR), COBALT, OPAL, Multlin, Clustal Omega, Clustal W2.0, or Clustal X2.0 software. For example, percentage of “sequence identity” can be determined by comparing two optimally aligned sequences over a comparison window, where the fragment of the nucleic acid sequence in the comparison window may comprise additions or deletions (e.g., gaps or overhangs) as compared to the reference sequence (i.e., a segment of nucleic acids that is used for alignment purposes against a query sequence which does not include additions or deletions) for optimal alignment of the two sequences. The percentage can be calculated by determining the number of positions at which the identical nucleotide, nucleoside, or nucleobase occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity. The output is the percent identity of the subject sequence with respect to the query sequence. For example, a nucleic acid may be described UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ herein as comprising a sequence that is at least X% identical to another nucleic acid (e.g., wherein “X” is 75 and the sequence is at least 75% identical to the other nucleic acid, such as 75- 80%, 80-85%, 85-90%, 90-95%, or 95-100% identical to the other nucleic acid) provided that the sequence is at least X% identitcal to at least one portion of the other nucleic acid (e.g., a segment of contiguous nucleotides located in the other nucleic acid). In some embodiments, engineered template nucleic acids, and transgenes, vectors, and recombinant viral genomes thereof as described herein comprise any one or more of the nucleic acid sequences set forth in Table 3. In some embodiments, engineered template nucleic acids, and transgenes, vectors, and recombinant viral genomes thereof as described herein comprise a nucleic acid sequence encoding an amino acid sequence set forth in Table 3. *The left-most column of the above table (Table 3) showcases sequence annotations corresponding to the sequence in the middle column. It should be understood that the same sequence annotation may be used more than once to identify distinct components of the engineered nucleic acid (e.g., for SEQ ID NO: 7, “first HA” and “LILRB1-intron7” are distinct sequences both annotated with normal text, wherein left homology arm (HA) = normal text, LILRB1-intron 5 = double-underlined text, SA sequence = single underlined text, LILRB1-d3 = italicized text, LILRB1-intron6 = dash underlined text, LILRB1-d3 = bold text, SD sequence = bold and double underlined text, LILRB1-intron7 = normal text, and dot underlined text = second HA). **All homology arms were designed and aligned based on the mouse reference sequence NC_000078.7. ***The present disclosure also provides for engineered template nucleic acids comprising the reverse complement forms of any one of SEQ ID NOs: 3-4, 7-11^36-51, 53-55, or 76-79. ****The present disclosure also provides for nucleic acids comprising any one or more of the components, or a portion thereof (e.g., a sequence of 3, 4, 5, 6, 7, 8, 9, 10, 10-25, 25-50, 50-100, 100-250, 250-500, 500-1,000, or more than 1,000 nucleotides), which are annotated in the left- most column in Table 3 and comprised in the engineered template nucleic acid sequences in the middle column of Table 3 (see, e.g., components and nucleotide sequences annotated with normal text, single-underlined text, double-underlined text, bold text, italicized text, dot underlined text, or any combination thereof). For example, the present disclosure provides for an engineered template nucleic acid, wherein the heterologous nucleic acid in a sequence described UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ in Table 3 is utilized and one or both of the homology arms in the same sequence described in Table 3 are replaced with a different homology arm described herein, such as a homology arm that hybridizes with a different target sequence in the mouse immunoglobulin locus or in a human immunoglobulin locus (see, e.g., the nucleotide sequences described in Tables 1-2, such as GenBank Reference Nos. NG_005838.1, NG_001019.6, and^NC_000078.7). As a further example, the present disclosure provides for an engineered template nucleic acid, wherein the heterologous nucleic acid in a sequence described in Table 3 is replaced with a different heterologous nucleic acid described herein and either both of the homology arms in the same sequence described in Table 3 are utilized or one or one of the homology arms is replaced with a different homology arm described herein. Table 3. Non-Limiting Examples of Engineered Template Nucleic Acids and Protein Products Thereof UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ Homology Arms In some embodiments, engineered template nucleic acids of the present disclosure comprise a first homology arm and a second homology arm which flank a heterologous nucleic acid. In some embodiments, a “homology arm” comprises sequences with homology to target sequences in a target site. A sequence with “homology” to a target sequence, refers to a sequence that is able to hybridize with the DNA, forming a stable duplex. In some embodiments, the ability to hybridize will depend on the length of the reverse complementary nucleic acid sequence of the homology arm. In some embodiments, the longer the homology arm the more stable the duplex will be between the homology arm and target sequence. “Identical to”, as it relates to a homology arm and its target sequence, refers to a homology arm sequence that is known to have, or is expected to have, 100% identity to a target sequence without introducing any gaps, deletions, overhangs, etc. during a suitable alignment process. Such alignments may be made using target site sequences obtained from publicly available information (e.g., deposits made in sequence online banks / databases) and / or DNA sequencing data for a population of B cells in vitro, or in a subject. In some embodiments, homology to the target sequence is found in homology arm sequences that comprise stretches of nucleotides that are identical to the target sequence. For example, in UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ some embodiments, wherein a homology arm comprises homology to a target sequence, the homology comprises a nucleotide sequence that is identical to at least one portion of the target sequence (e.g., a segment of contiguous nucleotides located in the target sequence, such as a segment of contigious nucleotides located in any one of the nucleotide sequences described in Tables 1-2) or to the reverse complement thereof. In some embodiments, a homology arm comprises sequences that differ from a target sequence by one or more (e.g., approximately 2, 3, 4, or 5) nucleotides. In some embodiments, a homology arm comprises 100% identity to a target sequence. In some embodiments, homology arms of engineered template nucleic acids of the present disclosure comprise sequences of 20-2000 nucleotides in length. In some embodiments, homology arms comprise approximately 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90- 100, 100-125, 125-150, 150-175, 175-200, 200-225, 225-250, 250-275, 275-300, 300-325, 325- 350, 350-375, 375-400, 400-425, 425-450, 450-475, 475-500, 500-525, 525-550, 550-575, 575- 600, 600-625, 625-650, 650-675, 675-700, 700-725, 725-750, 750-775, 775-800, 800-825, 825- 850, 850-875, 875-900, 900-925, 925-950, 950-975, 975-1000, 1000-1050, 1050-1100, 1100- 1150, 1150-1200, 1200-1250, 1250-1300, 1300-1350, 1350-1400, 1400-1450, 1450-1500, 1500- 1550, 1550-1600, 1600-1650, 1650-1700, 1700-1750, 1750-1800, 1800-1850, 1850-1900, 1900- 1950, or 1950-2000 nucleotides in length. However, in some embodiments, a homology arm comprises greater than 2000 nucleotides in length. In some embodiments, a first homology arm and a second homology arm comprise an equal number of nucleotides. In some embodiments, a first homology arm and a second homology arm comprise a nonequal number of nucleotides. In some embodiments, the lengths of the first and second homology arms may differ by approximately 1-5, 5-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-125, 125-150, 150-175, 175-200, 200-225, 225- 250, 250-275, 275-300, 300-325, 325-350, 350-375, 375-400, 400-425, 425-450, 450-475, 475- 500 or more nucleotides in length. In some embodiments, the lengths of the first and second homology arms may differ by approximately, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more nucleotides in length. In some embodiments, the first homology arm is longer than the second homology arm. In some embodiments, the second homology arm is longer than the first homology arm. UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ In some embodiments, homology arms comprise homology to target sequences found within or proximal (see, e.g., FIGs.1A-1B) to an active S region (see, e.g., the nucleotide sequences described in Tables 1-2, such as GenBank Reference Nos. NG_005838.1, NG_001019.6, and^NC_000078.7). In some embodiments, a first homology arm and a second homology arm in an engineered template nucleic acid hybridize with a first target sequence and a second target sequence, respectively. In some embodiments, the directionality of the homology arms relative to the target sequences may be in any orientation as long as homology arms comprise the reverse complement of their respective target sequences. In some embodiments, a homology arm comprises homology to a target sequence proximal an active S region. In some embodiments, a sequence “proximal to an active S region” refers to Ig heavy chain locus sequences that are approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1-3, 1- 4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 2-7, 7-12, 12-17, 17-22, 22-27, 27-32, 32-37, 37-42, 42-47, 47- 50, 3-8, 8-13, 13-18, 18-23, 23-28, 28-33, 33-38, 38-43, 43-48, 48-50, 4-9, 9-14, 14-19, 19-24, 24-29, 29-34, 34-39, 39-44, 44-49, 49-50, 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 50-60, 55-65, 60-70, 65-75, 70-80, 75-85, 80-90, 85-95, 90-100, 95-105, 100-120, 110- 130, 120-140, 130-150, 140-160, 150-170, 160-180, 170-190, 180-200, 190-200, 200-300, 250- 350, 300-400, 350-450, 400-500, 450-550, 500-600, 550-650, 600-700, 650-750, 700-900, 800- 1000, 900-1000, or 1000-1100, or more (e.g., 1500, 2000, 2500, etc.) nucleotides upstream or downstream of an active S region. In some embodiments, a homology arm comprises homology to a target sequence upstream and proximal to an active S region. In some embodiments, a homology arm comprises homology to a target sequence downstream and proximal to an active S region. In some embodiments, a homology arm comprises a sequence comprising approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 2-7, 7-12, 12-17, 17-22, 22-27, 27-32, 32-37, 37-42, 42-47, 47-50, 3-8, 8-13, 13-18, 18-23, 23-28, 28-33, 33-38, 38-43, 43-48, 48-50, 4-9, 9-14, 14-19, 19-24, 24-29, 29-34, 34-39, 39-44, 44-49, 49-50, 5-10, 10-15, 15-20, 20- 25, 25-30, 30-35, 35-40, 40-45, 45-50, 50-60, 55-65, 60-70, 65-75, 70-80, 75-85, 80-90, 85-95, 90-100, 95-105, 100-120, 110-130, 120-140, 130-150, 140-160, 150-170, 160-180, 170-190, 180-200, 190-200, 200-300, 250-350, 300-400, 350-450, 400-500, 450-550, 500-600, 550-650, 600-700, 650-750, 700-900, 800-1000, or 900-1000, or more nucleotides that are homologous to a target sequence upstream and proximal to an active S region or downstream and proximal to an active S region. In some embodiments, a sequence proximal to an active S region comprises UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ sequences in at least one of the human VDJ exons, the E^ enhancer, the I^ intron, the S^ region, the Cµ exon, the C^ exon, the I^3intron, the S^3region, the C^3exon, the I^1intron, the S^1region, the C^1exon, the I^1intron, the S^1region, the C^1exon, the ^13’ regulatory region (3’ RR), I^2 intron, the S^2 region, the C^2 exon, the I^4 intron, the S^4 region, the C^4 exon, the I^ intron, the S^ region, the C^ exon, the I^2intron, the S^2region, C^2exon,,and ^23’ regulatory region (3’ RR), or an intervening genomic sequence thereof. In some embodiments, a sequence proximal to an active S region comprises sequences located in the first J segment of human VDJ, the human C^2exon, and / or any intervening sequence between the first J segment of human VDJ and the human C^2exon thereof. In some embodiments, a sequence proximal to an active S region comprises sequences in at least one of the mouse VDJ exons, E^ enhancer, I^ intron, S^ region, C^ exon, C^ exon, I^3 intron, S^3 region, C^3 exon, I^1 intron, S^1 region, C^1 exon, I^2b intron, S^2bregion, C^2bexon, I^2^intron, S^2^region, C^2^exon, I^ intron, S^ region, C^ exon, I^ intron, S^ region, C^ exon, 3’ regulatory region (3’ RR), CTCF binding element (CBE), or an intervening genome sequence thereof. In some embodiments, a sequence proximal to an active S region comprises sequences located in the first J segment of mouse VDJ, the mouse C^ exon, and / or any intervening sequence between the first J segment of mouse VDJ and the mouse C^ exon thereof. In some embodiments, one or both homology arms comprise homology to target sequences proximal to an active S region. In some embodiments, one homology arm comprises homology to a target sequence upstream and proximal to an active S region, and the other homology arm comprises homology to a target sequence downstream and proximal to an active S region. In some embodiments, both homology arms comprise homology to respective target sequences proximal to the same active S region (see, e.g, FIG.1B, target site 3 engineered template nucleic acid) or different active S regions (see, e.g, FIG.1A, target site 3 engineered template nucleic acid). In some embodiments, a homology arm comprises homology to target sequences within an active S region. In some embodiments, target sequences within an active S region comprises Ig heavy chain locus sequences that are found within a human S^ region, human S^3 region,human S^1region, human S^1region, human S^2region, human S^4region, or human S^ region.In some embodiments, target sequences within an active S region comprises sequences within a mouse S^ region, mouse S^3 region, mouse S^1 region, mouse S^2b region, mouse S^2^ region, mouse S^ region, or mouse S^ region. In some embodiments, a homology arm comprises a UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ sequence comprising approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1- 10, 2-7, 7-12, 12-17, 17-22, 22-27, 27-32, 32-37, 37-42, 42-47, 47-50, 3-8, 8-13, 13-18, 18-23, 23-28, 28-33, 33-38, 38-43, 43-48, 48-50, 4-9, 9-14, 14-19, 19-24, 24-29, 29-34, 34-39, 39-44, 44-49, 49-50, 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 50-60, 55-65, 60-70, 65-75, 70-80, 75-85, 80-90, 85-95, 90-100, 95-105, 100-120, 110-130, 120-140, 130-150, 140- 160, 150-170, 160-180, 170-190, 180-200, 190-200, 200-300, 250-350, 300-400, 350-450, 400- 500, 450-550, 500-600, 550-650, 600-700, 650-750, 700-900, 800-1000, or 900-1000, or more nucleotides that are homologous to an active S region. In some embodiments, one or both homology arms comprise homology to target sequences within an active S region. In some embodiments, both homology arms comprise homology to respective target sequences within the same active S region (see, e.g, FIG.1B, target site 1 engineered template nucleic acid) or different active S regions (see, e.g, FIG.1A, target site 1 engineered template nucleic acid). In some embodiments, one homology arm comprises homology to a target sequence proximal an active S region and the other homology arm comprises homology to a target sequence within an active S region, such as the same active S region (see, e.g, FIG.1B, target site 2 engineered template nucleic acid) or different active S regions (see, e.g, FIG.1A, target site 2 engineered template nucleic acid). In some embodiments, homology arms comprise homology to target sequences that span the boundaries of an active S region and a sequence proximal to an active S region. In some embodiments, one or both homology arms comprise homology to target sequences that span the boundaries of an active S region and sequences proximal to the active S region. In some embodiments, the portion of a homology arm (e.g., either the 5’ or 3’ portion) homologous to a target sequence in an active S region is approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1-3, 1-4, 1-5, 1- 6, 1-7, 1-8, 1-9, 1-10, 2-7, 7-12, 12-17, 17-22, 22-27, 27-32, 32-37, 37-42, 42-47, 47-50, 3-8, 8- 13, 13-18, 18-23, 23-28, 28-33, 33-38, 38-43, 43-48, 48-50, 4-9, 9-14, 14-19, 19-24, 24-29, 29- 34, 34-39, 39-44, 44-49, 49-50, 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 50-60, 55-65, 60-70, 65-75, 70-80, 75-85, 80-90, 85-95, 90-100, 95-105, 100-120, 110-130, 120- 140, 130-150, 140-160, 150-170, 160-180, 170-190, 180-200, 190-200, 200-300, 250-350, 300- 400, 350-450, 400-500, 450-550, 500-600, 550-650, 600-700, 650-750, 700-900, 800-1000, or 900-1000, or more nucleotides long. In some embodiments, the portion of the homology arm (e.g., either the 5’ or 3’ portion) homologous to a target sequence proximal to an active S region UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ is approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 2-7, 7-12, 12- 17, 17-22, 22-27, 27-32, 32-37, 37-42, 42-47, 47-50, 3-8, 8-13, 13-18, 18-23, 23-28, 28-33, 33- 38, 38-43, 43-48, 48-50, 4-9, 9-14, 14-19, 19-24, 24-29, 29-34, 34-39, 39-44, 44-49, 49-50, 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 50-60, 55-65, 60-70, 65-75, 70-80, 75- 85, 80-90, 85-95, 90-100, 95-105, 100-120, 110-130, 120-140, 130-150, 140-160, 150-170, 160 180, 170-190, 180-200, 190-200, 200-300, 250-350, 300-400, 350-450, 400-500, 450-550, 500- 600, 550-650, 600-700, 650-750, 700-900, 800-1000, or 900-1000, or more nucleotides long. In some embodiments, homology arms comprise homology to target sequences found proximal to at least one DSB in a target site. In some embodiments, homology arms comprise homology to target sequences flanking at least one AID target motif in an active S region. In some embodiments, an AID target motif comprises, on the 5’ to 3’ strand, a sequence of the structure: 5’ - RGYW - 3’, wherein R = A / G, Y = C / T, and W = A / T. In some embodiments, an AID target motif comprises, on the 3’ to 5’ strand, a sequence of the structure: 5’ - WRCY - 3’ which comprises the C that AID targets. In some embodiments, wherein a target site comprises a single active S region, one homology arm comprises homology to a target sequence upstream of an AID target motif in the active S region and the other homology arm comprises homology to a target sequence downstream of said AID target motif in the active S region. In some embodiments, wherein a target site comprises a single active S region, the target site may comprise a single DSB. For instance, before HDR, a target site may comprise (from 5’ to 3’): [VDJ]-[I^]-[S^]-[C^], wherein underline indicates sequences undergoing transcription and bold indicates the active S region comprising AID target motifs. After HDR, using the following example of an engineered template nucleic acid, as a substrate: [HA to I^ target seq.]-[heterologous nucleic acid]-[HA to C^ target seq.], the engineered target site would comprise the following (shown 5’ to 3’): UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ [VDJ]-[I^]-[heterologous nucleic acid]-[C^], thereby producing an engineered target site comprising an IgM coding sequence, wherein the CHregion comprises the heterologous nucleic acid. In some embodiments, wherein a target site comprises two active S regions, one homology arm comprises homology to a target sequence upstream of an AID target motif in the most 5’ active S region and the other homology arm comprises homology to a target sequence downstream of an AID target motif in the most 3’ active S region. In some embodiments, wherein a target site comprises two active S regions, the target site may comprise two DSBs (e.g., a first DSB in a first active S region and a second DSB in a second active S region). For instance, before HDR, a target site may comprise (from 5’ to 3’): [VDJ]-[I^]-[S^]-[C^]-[C^]-[I^1]-[S^1]-[C^1], wherein underline indicates regions undergoing transcription and bold indicates the active S regions comprising AID target motifs. After HDR, using the following example of an engineered template nucleic acid, as a substrate: [HA to S^ target seq.]-[heterologous nucleic acid]-[HA to C^1target seq.], the engineered site would comprise the following (shown 5’ to 3’): [VDJ]-[I^]-[heterologous nucleic acid ]-[C^1], thereby producing an engineered target site comprising an IgG1 coding sequence, wherein the CHregion comprises the heterologous nucleic acid. In some embodiments, a sequence “proximal to at least one DSB in a target site” or “proximal to at least one AID target motif in an active S region” refers to Ig heavy chain locus sequences that are approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 2-7, 7-12, 12-17, 17-22, 22-27, 27-32, 32-37, 37-42, 42-47, 47-50, 3-8, 8-13, 13-18, 18-23, 23- 28, 28-33, 33-38, 38-43, 43-48, 48-50, 4-9, 9-14, 14-19, 19-24, 24-29, 29-34, 34-39, 39-44, 44- UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ 49, 49-50, 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 50-60, 55-65, 60-70, 65-75, 70-80, 75-85, 80-90, 85-95, 90-100, 95-105, 100-120, 110-130, 120-140, 130-150, 140- 160, 150-170, 160-180, 170-190, 180-200, 190-200, 200-300, 250-350, 300-400, 350-450, 400- 500, 450-550, 500-600, 550-650, 600-700, 650-750, 700-900, 800-1000, 900-1000, or 1000- 1100, or more (e.g., 1500, 200, 2500, etc.) nucleotides upstream or downstream of a DSB in a target site or an AID target motif in an active S region. In some embodiments, an engineered template nucleic acid comprises a first homology arm with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to any one of the nucleotide sequences set forth in Tables 1-4 (e.g., any one of SEQ ID NOs: 14, 16, 18, 20, or 21) or a reverse complement thereof. In some embodiments, an engineered template nucleic acid comprises a first homology arm according to any one of the nucleotide sequences set forth in Table 4 (e.g., any one of SEQ ID NOs: 14, 16, 18, 20, or 21) or a reverse complement thereof. In some embodiments, an engineered template nucleic acid comprises a second homology arm with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to any one of the nucleotide sequences set forth in Tables 1-4 (e.g., any one of SEQ ID NOs: 15, 17, 19, or 27) or a reverse complement thereof. In some embodiments, an engineered template nucleic acid comprises a second homology arm according to any one of the nucleotide sequences set forth in Table 4 (e.g., any one of SEQ ID NOs: 15, 17, 19, or 27) or a reverse complement thereof. In some embodiments, engineered template nucleic acids, and transgenes, vectors, and recombinant viral genomes thereof described herein comprise any of the homology arm sequences set forth in Table 4. Table 4. Non-Limiting Examples of Homology Arm Sequences UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ *The present disclosure also provides for engineered template nucleic acids comprising the reverse complement forms of the sequences of any one of SEQ ID NOs: 14-21, 27, or 56-66. Heterologous Nucleic Acids In some embodiments, an engineered template nucleic acids of the present disclosure comprise a heterologous nucleic acid flanked by, at least, a first homology arm and a second homology arm. As used herein, “heterologous nucleic acid” refers to any sequence that is not normally found at a given target site. In some embodiments, a heterologous nucleic acid comprises, one or more heterologous nucleotides relative to the target site. In some embodiments, heterologous nucleic acids of the present disclosure comprise 1-3000 nucleotides in length. In some embodiments, a heterologous nucleic acid is approximately 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 900-1000, 1000-1100, 1100-1200, 1200-1300, 1300-1400, 1400-1500, 1500-1600, 1600-1700, 1700-1800, 1800-1900, 1900-2000, 2000-2100, 2100-2200, 2200-2300, 2300-2400, 2400-2500, 2500-2600, 2600-2700, 2700-2800, 2800-2900, or 2900-3000 nucleotides long. In some embodiments, a heterologous nucleic acid is approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 2-7, 7-12, 12-17, 17-22, 22-27, 27-32, 32-37, 37-42, 42-47, 47-50, 3-8, 8-13, 13-18, 18-23, 23-28, 28-33, 33-38, 38-43, 43-48, 48-50, 4-9, 9-14, 14-19, 19-24, 24-29, 29-34, 34-39, 39-44, 44-49, 49-50, 5-10, 10- 15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 50-60, 55-65, 60-70, 65-75, 70-80, 75-85, 80-90, 85-95, 90-100, 95-105, 100-120, 110-130, 120-140, 130-150, 140-160, 150-170, 160-180, 170-190, 180-200, 190-200, 200-300, 250-350, 300-400, 350-450, 400-500, 450-550, 500-600, 550-650, 600-700, 650-750, 700-900, 800-1000, 900-1000, 950-1000, 1000-1300, 1100-1400, 1200-1500, 1300-1600, 1400-1700, 1500-1800, 1600-1900, 1700-2000, 1800-2100, 1900-2200, 2000-2500, 2100-2600, 2200-2700, 2300-2800, 2400-2900, or 2500-3000 nucleotides long. In some embodiments, hybridization of the engineered template nucleic acid to the target site during HDR comprises base-pairing of the homology arms with their target sequences. However, in some embodiments, the heterologous nucleic acid may be designed with a degree of homology to the target site which also promotes hybridization of the engineered template nucleic acid with the target site. In some embodiments, the heterologous nucleic acid comprises at least 99.9%, at least 99.8%, at least 99.7%, at least 99.6%, at least 99.5%, at least 99%, at least 98%, UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ at least 97%, at least 96%, at least 95%, at least 94%, at least 93%, at least 92%, at least 91%, at least 90%, at least 89%, at least 88%, at least 87%, at least 86%, at least 85%, at least 84%, at least 83%, at least 82%, at least 81%, at least 80%, at least 79%, at least 78%, at least 77%, at least 76%, at least 75%, at least 74%, at least 73%, at least 72%, at least 71%, at least 70%, at least 69%, at least 68%, at least 67%, at least 66%, at least 65%, at least 65%, at least 64%, at least 63%, at least 62%, at least 61%, at least 60%, at least 59%, at least 58%, at least 57%, at least 56%, at least 55%, at least 54%, at least 53%, at least 52%, at least 51%, or at least 50% identity to sequences in a target site. In some embodiments, a heterologous nucleic acid is 1-3%, 1-4%, 1-5%, 1-6%, 1-7%, 1-8%, 1-9%, 1-10%, 20-25%, 5-10%, 5-15%, 5-20%, 10-20%, 15- 20%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-60%, 55-65%, 60-70%, 65-75%, 70-80%, 75-85%, 80-90%, 85-95%, 90-95%, or 95-99% identical to sequences in a target site. In some embodiments, one or more portions (e.g., a stretch of contiguous nucleotides) of the heterologous nucleic acid sequence comprises 100% identity to sequences in the target site. In some embodiments, a heterologous nucleic acid sequence comprises no identity to a target site described herein. In some embodiments, a heterologous nucleic acid comprises approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 5-10, 5-15, 5-20, 10-20, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 50-60, 55-65, 60-70, 65-75, 70-80, 75- 85, 80-90, 85-95, 90-100, 95-105, 100-120, 110-130, 120-140, 130-150, 140-160, 150-170, 160- 180, 170-190, 180-200, 190-200, 200-300, 250-350, 300-400, 350-450, 400-500, 450-550, 500- 600, 550-650, 600-700, 650-750, 700-900, 800-1000, 900-1000, 950-1000, 1000-1300, 1100- 1400, 1200-1500, 1300-1600, 1400-1700, 1500-1800, 1600-1900, 1700-2000, 1800-2100, 1900- 2200, 2000-2500, 2100-2600, 2200-2700, 2300-2800, 2400-2900, or 2500-3000 nucleotides heterologous to a target site. In some embodiments, a heterologous nucleic acid introduces a regulatory sequence described herein into a target site. In some embodiments, a heterologous nucleic acid is integrated into a target site via HDR in order to generate a sequence change in the Ig heavy chain locus. In some embodiments, a heterologous nucleic acid changes (e.g., creates an insertion, deletion, and / or substitution) the target site at approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 5-10, 5-15, 5-20, 10-20, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 50-60, 55-65, 60-70, 65-75, 70-80, 75-85, 80-90, 85-95, 90-100, 95-105, 100-120, 110-130, 120-140, 130-150, 140-160, 150- 170, 160-180, 170-190, 180-200, 190-200, 200-300, 250-350, 300-400, 350-450, 400-500, 450- UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ 550, 500-600, 550-650, 600-700, 650-750, 700-900, 800-1000, 900-1000, 950-1000, 1000-1300, 1100-1400, 1200-1500, 1300-1600, 1400-1700, 1500-1800, 1600-1900, 1700-2000, 1800-2100, 1900-2200, 2000-2500, 2100-2600, 2200-2700, 2300-2800, 2400-2900, or 2500-3000 nucleotide positions. In some embodiments, a heterologous nucleic acid is integrated in one or more of the human VDJ exons, the E^ enhancer, the I^ intron, the S^ region, the Cµ exon, the C^ exon, the I^3intron, the S^3region, the C^3exon, the I^1intron, the S^1region, the C^1exon, the I^1intron, the S^1 region, the C^1 exon, the ^13’ regulatory region (3’ RR), I^2 intron, the S^2 region, the C^2exon, the I^4intron, the S^4region, the C^4exon, the I^ intron, the S^ region, the C^ exon, the I^2intron, the S^2region, C^2exon,,and ^23’ regulatory region (3’ RR), and / or an intervening genomic sequence thereof. In some embodiments, a heterologous nucleic acid is integrated in one or more of the mouse VDJ exons, E^ enhancer, I^ intron, S^ region, C^ exon, C^ exon, I^3 intron, S^3region, C^3exon, I^1intron, S^1region, C^1exon, I^2bintron, S^2bregion, C^2bexon, I^2^ intron, S^2^ region, C^2^ exon, I^ intron, S^ region, C^ exon, I^ intron, S^ region, C^ exon, 3’ regulatory region (3’ RR), CTCF binding element (CBE), and / or any genomic sequence intervening said elements. In some embodiments, a heterologous nucleic acid generates an insertion of at least one nucleotide. In some embodiments. a heterologous nucleic acid generates a deletion of at least one nucleotide. In some embodiments, a heterologous nucleic acid generates a substitution of at least one nucleotide. In some embodiments, a heterologous nucleic acid generates any combination of insertions, deletions, and / or substitutions in the edited target Ig heavy chain locus. In some embodiments, a heterologous nucleic acid generates at least one corrective nucleotide change in a mutant target site thereby generating a wild-type Ig heavy chain locus. In some embodiments, a heterologous nucleic acid is designed to correct a mutation in a CH gene. In some embodiments, a heterologous nucleic acid is designed to mutate a regulatory sequence of a CH gene coding sequence. In some embodiments, a heterologous nucleic acid mutates at least one AID target motif in a target site in order to prevent further editing of said target site. In some embodiments, a heterologous nucleic acid introduces at least one AID target motif in a target site. In some embodiments, a heterologous nucleic acid generates a mutation in a non-coding sequence (e.g., a promoter, an enhancer, an intron, a poly(A) signal, etc.) of the Ig heavy chain locus. In some embodiments, after HDR, a heterologous nucleic acid introduces into a target site at least one of the following: a synonymous mutation, a nonsynonymous, a conservative mutation, a UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ nonconservative mutation, a frameshift, a premature stop codon, a splice donor site, a splice acceptor site, an intron, or any combination thereof. In some embodiments, a heterologous nucleic acid may introduce a non-coding sequence, a coding sequence, or both into a target site. In some embodiments, a heterologous nucleic acid changes the Ig isotype produced by a B cell. For example, a B cell expressing a first Ig isotype (e.g., a B cell expressing IgM, such as an IgM memory B cell) can be engineered to express a second Ig isotype (e.g., engineered to express IgG1, such as by subjecting the B cell to editing conditions that utilize an engineered template nucleic acid comprising the following components:^ [HA1 targeting Iµ (upstream Sµ)] - [heterologous nucleic acid comprising exons coding for IgM and IgM polyA tail] - [HA2 targeting 3’ portion of S^1 or downstream of S^1]). In some embodiments, a heterologous nucleic acid comprises a sequence that does not change the structure of a synthesized Ig. In some embodiments, a heterologous nucleic acid comprises a sequence that changes the expression levels, rate, degradation, and / or stability of a synthesized Ig. For example, in some embodiments, a heterologous nucleic acid comprises a sequence that introduces a stabilizing mutation into an immunoglobulin, such as a mutation in the CH2 region of IgG1 (e.g., a Q295F / Y296A mutation in human IgG1). In some embodiments, an IgG1 amino acid sequence is altered by utilizing an engineered template nucleic acid to edit the immunoglobulin locus of B cells expressing IgG1, wherein the engineered template nucleic acid comprises the following components: [HA1 targeting upstream or 5’ region of Sµ] - [heterologous acid a portion of the CH1-CH2 of IgG1 with a stabilizing mutation(s)] - [HA2 targeting CH3 of IgG1]; or [HA1 targeting 3’ region of S^1 towards CH1 of S^] - [heterologous acid comprising a portion of the CH2 of IgG1 with a stabilizing mutation(s)] - [HA2 targeting CH3 of IgG1]. In some embodiments, a heterologous nucleic acid introduces a regulatory sequence described herein (e.g., a promoter, an enhancer, an intron, a poly(A) signal, etc.) into a target site. In some embodiments, a heterologous nucleic acid introduces a regulatory sequence (e.g., a promoter, such as a core promoter, an enhancer, an intron, a poly(A) signal, a splice acceptor site, a splice donor site, etc.) into a target site that operably links CH gene to the regulatory sequence and / or a nucleotide sequence encoding an amino acid sequence that regulates an immunoglobulin amino acid sequence post-translationally (e.g., a signal peptide, a furin cleavage site, etc.). In some embodiments, a heterologous nucleic acid comprises a sequence that will be included in a synthesized Ig. In some embodiments, a heterologous nucleic UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ acid comprises a sequence encoding a peptide, a protein motif, a protein domain, or a protein. In some embodiments, a heterologous nucleic acid comprises a sequence encoding a peptide linker. In some embodiments, a heterologous nucleic acid comprises a sequence encoding an antigen- binding fragment, an enzyme or an enzymatic domain, a growth factor, a hormone, a signaling peptide, or a cytokine. In some embodiments, a heterologous nucleic acid comprises a sequence encoding an enzyme substrate (e.g., a protease substrate such as a furin protease). In some embodiments, a heterologous nucleic acid comprises a sequence encoding a self-cleaving peptide, such as a 2A peptide (e.g., a P2A peptide, an F2A peptide, an E2A peptide, or a T2A peptide. In some embodiments, a heterologous nucleic acid comprises a reporter such as luciferase, ^-galactosidase, or a fluorescent protein. In some embodiments, a heterologous nucleic acid comprises a modified immunoadhesin, such as an Fc-fusion protein. In some embodiments, a heterologous nucleic acid comprises the antigen-binding domain of an Fc-fusion protein (e.g., domains 1 and 2 human CD4, TNF domains) or the whole Fc-fusion protein (e.g., Embrel, CD4-IgG2, or CD4-IgG1). In some embodiments, a heterologous nucleic acid comprises an LFA3-IgG1 fusion protein or an TNFR-IgG1 fusion protein. In some embodiments, a heterologous nucleic acid comprises a sequence that can be inserted at the elbow region of an immunoglobulin (e.g., the linker between the VDJ variable domain and CH1 on an antibody molecule) or a fragment thereof (e.g., wherein the elbow region comprises an amino acid sequence encoded by a genomic sequence comprising a switch region). In some embodiments, a heterologous nucleic acid comprises a second recognition domain to be inserted at the elbow region of an immunoglobulin or a fragment thereof. In some embodiments, a heterologous nucleic acid comprises a sequence encoding an ALFA tag amino acid sequence (see, e.g., the ALFA tag sequences described in Tables 3 and 5). In some embodiments, a heterologous nucleic acid comprises sequences for producing antibodies comprising genetically engineered variable domains. In some embodiments, a heterologous nucleic acid comprises one or more sequences encoding a neutralizing antibody, such as an HIV neutralizing antibody or a variant thereof (e.g., an evolved and / or optimized variant of an HIV neutralizing antibody). In some embodiments, a heterologous nucleic acid comprises a sequence encoding erythropoietin (EPO) or a variant thereof (e.g., EPOR150A-huGYPA variant). In some embodiments, a heterologous nucleic acid comprises a sequence encoding glucagon-like peptide 1 (GLP-1) or a variant thereof. In some emebodiments, a heterologous nucleic acid comprises a sequence encoding clotting factor VIII UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ (e.g., a heterologous nucleic acid comprised in an engineered template nucleic acid that can be administered to a subject characterized as having hemophilia). In some emebodiments, a heterologous nucleic acid comprises a sequence encoding alpha-L-iduronidase (e.g., a heterologous nucleic acid comprised in an engineered template nucleic acid that can be administered to a subject characterized as having Hurler’s syndrome). In some embodiments, a heterologous nucleic acid comprise a sequence encoding an RNA (e.g., an RNA encoding a peptide or protein) and homology arms are designed to inserted the sequence into the target site such that exression of the RNA is regulated by E^ (see, e.g., the engineered template nucleic acid designs in FIGs.9A-9C and MT86v1, MT86v2, MT86v3, and MT86v4 as disclosed in Table 3). In some embodiments, the peptide or protein is an Fc-fusion protein, such as an TNF-Fc or CTLA4-Fc (e.g., wherein the engineered template nucleic acid is utilized in the treatment of a subject characterized as having rheumatoid arthritis and / or as exhibiting one or more signs or symptoms of graft rejection). In some embodiments, the peptide or protein comprise CAP256- VRC26.25 or a portion thereof. For example, in some embodiments, the portion CAP256- VRC26.25 comprises a CDR, such as CDR3 (e.g., wherein the sequence encoding the CDR is inserted into a sequence encoding an elbow region of an immunoglobulin, such as the elbow region of IgGM or IgG1, such as wherein the CDR comprises the amino acid sequence^ ECEEWWSDYYDFGKQLPCAKSR (SEQ ID NO: 80) and / or is located in an amino acid sequence comprising DLREDECEEWWSDYYDFGKQLPCAKSRGGLVGIAD (SEQ ID NO: 81)) (see, e.g., dislosures related to CAP256-VRC26.25 in N. A. Doria-Rose et al., Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509:55- 62, 2014). In some embodiments, the peptide or protein is encoded by a gene, wherein an endogenous copy of the gene is non-functional, such as deleted, in a cell which has been edited with the engineered template nucleic acid. In some embodiments, the gene encodes factor VIII (e.g., wherein the engineered template nucleic acid is utilized in the treatment of a subject characterized as having hemophilia). In some embodiments, the gene encodes iduronidase (e.g., wherein the engineered template nucleic acid is utilized in the treatment of a subject characterized as having Hurler’s syndrome). In some embodiments, a heterologous nucleic acid comprises one or more LILRB1 domains (e.g., LILRB1 domains 3 and 4; see, e.g., nucleic acids comprising LILRB1 nucleotide sequences which are described herein, such as the sequences comprised in MT56, in Table 3 and Table 5) (e.g., wherein the engineered template nucleic acid UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ is utilized in the treatment of a subject characterized as having malaria; see, e.g., disclosures related to LILRB1 binding to malaria antigens in Chen et al. (2021). Structural basis of malaria RIFIN binding by LILRB1-containing antibodies. Nature, 592: 639–643). In some embodiments, a heterologous nucleic acid comprises a sequence encoding a human CD4 amino acid sequence (see, e.g., nucleic acids comprising a sequence encoding a human CD4 amino acid sequence, such as the sequences comprised in MT76v1 and MT76v2, in Table 3 and Table 5). In some embodiments, a heterologous nucleic acid is a codon-optimized sequence.^ In some embodiments, an engineered template nucleic acid is designed to generate a sequence encoding an engineered CD4-IgG1 fustion protein comprising CD4-domains 1 and 2 and domains CH2 and CH3 of IgG1. For example, in some embodiments, an engineered template nucleic acid is designed to integrate an antigen-binding portion of an Fc-fusion protein (e.g., CD4-domains 1 and 2) and one or more regulatory sequences described herein, while also deleting part of the native heavy chain (e.g., the CH1 or the splice acceptor of CH1) and mutating part of the native Fc (e.g., the hinge region). ^ In some embodiments, a heterologous nucleic acid comprises a nucleic acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to any one of the nucleotide sequences set forth in Tables 3 and 5 (e.g., any one of SEQ ID NOs: 3-4 or 22-25) or a reverse complement thereof. In some embodiments, a heterologous nucleic acid comprises the nucleic acid sequence of any one of the nucleotide sequences set forth in Tables 3 and 5 (e.g., any one of SEQ ID NOs: 3-4 or 22-25) or a reverse complement thereof. In some embodiments, a heterologous nucleic acid comprises a nucleic acid sequence encoding an amino acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to any one of the amino acid sequences set forth in Table 3 (e.g., any one of SEQ ID NOs: 1, 2, 5, or 6). In some embodiments, a heterologous nucleic acid comprises a nucleic acid sequence encoding any one of the amino acid sequences set forth in Table 3 (e.g., any one of SEQ ID NOs: 1, 2, 5, or 6). Non-limiting examples of heterologous nucleic acid sequences and amino acids sequences encoded by heterologous nucleic acids are shown in Table 5. UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ Table 5. Non-limiting Examples of Heterologous Nucleic Acids and Amino Acid Sequences Encoded Therein UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ Transgenes Other aspects of the present invention relate to transgenes comprising an engineered template nucleic acid described herein. The term “transgene” refers to any sequence that is not naturally found between inverted terminal repeats (ITRs) of rAAVs or long terminal repeats (LTRs) of lentiviruses and encodes at least one RNA to be expressed in a cell. In some embodiments, a transgene comprises an engineered template nucleic acid. An engineered template nucleic acid may, in some embodiments, be provided in a transgene or a recombinant virus thereof in order to promote transcription of a sequence comprising the engineered template nucleic acid. In some embodiments, the transgene encodes an mRNA that is translated into a protein. In some embodiments, the transgene comprises at least one regulatory sequence described herein. In some embodiments, the transgene comprises at least one regulatory sequence described herein which is operably linked to the engineered template nucleic acid. In some embodiments, a transgene may comprise a regulatory sequence 5' of the first homology arm. In some embodiments, a transgene comprises an enhancer 5' of the first homology arm. In some embodiments, a transgene comprises a nucleic acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to any one of the nucleotide sequences set forth in Tables 1-5 (e.g., any one of SEQ ID NOs: 3-4, 7-11, or 14-27) or a reverse complement thereof. In some embodiments, the transgene comprises any one of the nucleic acid sequences set forth in Tables 3-5 (e.g., any one of SEQ ID NOs: 3-4, 7-11, 14-25, or 27). Regulatory Sequences UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ Other aspects of the present disclosure relate to an engineered template nucleic acid that may comprise one or more regulatory sequences.^As used herein, a “regulatory sequence” is a DNA sequence which modulates the expression, stability, and / or levels of an RNA when operably linked to a gene sequence. In some embodiments, a heterologous nucleic acid comprises at least one regulatory sequence. In some embodiments, at least one regulatory sequence may be operably linked to an engineered template nucleic acid. In some embodiments, an engineered template nucleic acid is operably linked to at least one regulatory sequence and provided in a transgene or vector. In some embodiments, an engineered acid comprises one or more regulatory sequences that are not operably linked to the engineered template nucleic acid. As used herein, a nucleic acid sequence and regulatory sequences are said to be “operably linked” when they are covalently linked in such a way as to place the expression or transcription of the nucleic acid sequence under the influence or control of the regulatory sequences. For example, two DNA sequences are said to be operably linked if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation or (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences. Thus, a promoter region would be operably linked to a nucleic acid sequence if the promoter region were capable of effecting the transcription rate and / or level. In some embodiments, an engineered template nucleic acid described herein comprises one or more sequences that regulate transcription (e.g., any one or more of a promoter, an enhancer, a transcription factor binding sequence, a transcriptional start sequence, transcription termination sequence, etc.), one or more sequences that regulate translation (e.g., any one or more of a 5’ UTR, a translation initiation regulatory sequence, a Kozack sequence, a Shine- Dalgarno sequence, a start codon, a ribosome binding site, a 3’ UTR, a translation termination sequence, a stop codon, etc.), and / or one or more sequences that regulate splicing (e.g., any one or more of a binding site for small nuclear ribonucleoproteins, splicing acceptor sites, splicing donor sites, etc.). It should be appreciated that engineered template nucleic acids described herein can comprise a nucleotide sequence encoding an amino acid sequence that regulates a peptide or protein. For example, in some embodiments, an engineered template nucleic acid comprises a sequence (e.g., a sequence located in a heterologous nucleic acid) that encodes an amino acid sequence that promotes post-translational modification (e.g., cleavage, degradation, UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ phosphorylation, dephosphorylation, acetylation, deacetylation, lipidation, delipidation, glycosylation, deglycosylation, methylation, or demethylation) and / or regulates trafficking (e.g., trafficking that leads to extracellular secretion and / or trafficking to an organelle, such as trafficking of the peptide or protein to the cytoplasm, the endoplasmid reticulum, the golgi apparatus, the mitochondria, a vesicle, the endosome, or the nucleus) of a peptide or protein, such as a peptide or protein comprising the amino acid sequence that promotes the post- translational modification. Non-limiting examples of amino acid sequences that promote post- translational modifications of a peptide or protein include self-cleaving peptides (e.g., P2A, E2A, T2A, and F2A peptides), signal peptides, and recognition sites for enzymes (e.g., a protease cleavage site, a ubiquitinylation site, a phosphorylation site, a SUMOylation site, a farnesylation site, an acetylation site, a methylation site, or a glysoylation site). Non-limiting examples of amino acid sequences that regulate trafficking of a peptide or protein include signal peptides, recognition sites for enzyme, and binding sites for trafficking factors (e.g., proteins that regulate trafficking to the cytoplasm, the endoplasmid reticulum, the golgi apparatus, the mitochondria, a vesicle, the endosome, or the nucleus). In some embodiments, an engineered template nucleic acid comprises a plurality of sequences (e.g., two, three, four, five, or more than five amino acid sequences, such as wherein one or more of the sequences are located in a heterologous nucleic acid and / or wherein one or more of the sequences are located in a different region than the heterologous nucleic acid) that each encode an amino acid sequence that promotes post- translational modification and / or trafficking of a peptide or protein. In some embodiments, an engineered template nucleic acid described herein comprises a constitutive promoter. Constitutive promotes maintain constant expression of a gene (e.g., an engineered template nucleic acid provided in a transgene) regardless of the conditions or physiological state of a cell. Examples of constitutive promoters include, without limitation, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) (see, e.g., disclosures relaed to the CMV promoter in Boshart et al., Cell, 41:521-530 (1985)), the SV40 promoter, the dihydrofolate reductase promoter, the ^-actin promoter, the phosphoglycerol kinase (PGK) promoter, the CAG promoter, and the human elongation factor-1 alpha (EF1^) promoter [Invitrogen]. In some embodiments, a promoter is an RNA pol II promoter. In some embodiments, a promoter is an RNA pol III promoter, such as U6 or H1. In some embodiments, UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ a promoter is an RNA pol II promoter. In some embodiments, a promoter comprises a CMV enhancer (CMVe). In some embodiments, a promoter is a chicken ^-actin (CBA) promoter. In some embodiments, a promoter is a CMVe and a CBA promoter. In some embodiments, a promoter is a CAG promoter. In some embodiments, a promoter is an SCP1 promoter (see, e.g., the SCP1 promoter sequence indicated by dashed underline in the MT104 sequence described in Table 3). In some embodiments, an engineered template nucleic acid described herein comprises an inducible promoter. Inducible promoters allow regulation of gene expression and can be regulated by exogenously supplied compounds, environmental factors such as temperature, or the presence of a specific physiological state. Inducible promoters and inducible systems are available from a variety of commercial sources, including, without limitation, Invitrogen, Clontech, and Ariad. Examples of inducible promoters regulated by exogenously supplied promoters include the zinc-inducible sheep metallothionine (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system (WO 98 / 10088); the ecdysone insect promoter (see, e.g., disclosure related to the ecdysone insect promoter in No et al., Proc. Natl. Acad. Sci. USA, 93:3346-3351 (1996)), the tetracycline-repressible system (see, e.g., dsiclosures related to tetracycline-responsive sequences in Gossen et al., Proc. Natl. Acad. Sci. USA, 89:5547-5551 (1992)), the tetracycline-inducible system (see, e.g., dsiclosures related to tetracycline-responsive sequences in Gossen et al., Science, 268:1766-1769 (1995), see also Harvey et al., Curr. Opin. Chem. Biol., 2:512-518 (1998)), the RU486-inducible system (see, e.g., dsiclosures related to RU486-responsive sequences in Wang et al., Nat. Biotech., 15:239-243 (1997) and Wang et al., Gene Ther., 4:432- 441 (1997)) and the rapamycin-inducible system (see, e.g., dsiclosures related to rapamycin- responsive sequences in Magari et al., J. Clin. Invest., 100:2865-2872 (1997)). In some embodiments, other types of inducible promoters which may be useful are those which are regulated by a specific physiological state. In some embodiments, a promoter imparts tissue-specific gene expression capabilities. In some cases, tissue-specific regulatory sequences bind tissue-specific transcription factors that induce transcription in a tissue specific manner. In some embodiments, a tissue-specific promoter is an immune cell-specific promoter (e.g., a promoter which is active in a B cell). One such example is an Ig heavy chain promoter. UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ In some embodiments, a promoter described herein comprises and / or is linked to one or more sequences that promote the function of the promoter. In some embodiments, a promoter described herein further comprises an exonic sequence. In some embodiments, a promoter further comprises an intronic sequence. In some embodiments, a promoter further comprises a chicken beta-actin intron and / or an artificial intron. In some embodiments, a promoter further comprises a chimeric intron. In some embodiments, a promoter does not comprise an exonic sequence and / or an intronic sequence. In some embodiments, a promoter is a core promoter (e.g., a promoter comprising a short sequence and that can be associated with an enhancer to regulate expression of a gene, such as an SCP1 core promoter). In some embodiments, an engineered template nucleic acid described herein comprises a polyadenylation signal sequence. In some embodiments, a transgene comprises an engineered template nucleic acids inserted before any other 3’ regulatory sequence (e.g., a 3’ AAV ITR). In some embodiments, a poly(A) signal sequence is inserted following the engineered template nucleic acid 3' regulatory sequence (e.g., a 3' AAV ITR), which signals for the polyadenylation of transcribed mRNA molecules. In some embodiments, a poly(A) signal sequence is heterologous. In some embodiments, a poly(A) signal sequence is a synthetic poly(A) sequence (e.g., a non-naturally occurring poly(A) sequence that is, e.g., 20-100 nucleotides long). Examples of poly(A) signal sequences include, but are not limited to, bovine growth hormone (bGH) poly(A) signal sequence, SV-40 poly(A) signal sequence, and synthetic poly(A) signal sequences, which are known to cause polyadenylation of eukaryotic transgenes and efficient termination of translation (see, e.g., disclosures related to poly(A) signal sequences in Azzoni A R et al., J Gene Med.2007; 9(5):392-402). In some embodiments, other expression control elements, such as enhancer elements, or introns may also be found in engineered template nucleic acids described herein. In some embodiments, an engineered template nucleic comprises one or more (e.g., 1, 2, 3, etc.) introns. In some embodiments, an intron is included in a promoter described herein, for example, a CAG promoter or chicken beta-actin promoter. In some embodiments, an intron is included in a poly(A) signal sequence. CRISPR / Cas Systems UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ Further to the compositions and methods described herein that can be utilized to edit a target site (e.g., a target site located in an immunoglobulin locus (see, e.g., the nucleotide sequences described in Tables 1-2, such as GenBank Reference Nos. NG_005838.1, NG_001019.6, and^NC_000078.7)) targeted by activation-induced deaminase (AID), aspects of the application also relate to utilizing a CRISPR / Cas system (e.g., a system comprising a Cas protein described herein and a gRNA described herein) in combination with an engineered template nucleic acid described herein to edit a target site (e.g., a target site located in an immunoglobun locus). In some embodiments, a CRISPR / Cas system (e.g., a system comprising a Cas protein described herein and a gRNA described herein including, but not limited to a single-guide RNA (sgRNA)) is utilized to generate DNA damage (e.g., a DNA break, such as a double-stranded DNA break (DSB) or a single-stranded break (SSB)) in a sequence (e.g., a sequence that binds a gRNA) located within or proximal to a target site. In some embodiments, a Cas protein comprises endonuclease activity and the Cas protein cleaves both strands of a target site described herein, thereby introducing one or more DSBs into the target site. However, in some embodiments, a Cas protein is used to generate one or more SSBs in a target site described herein. For example, in some embodiments, a SSB in a target site is generated using a Cas protein with nickase activity. In some embodiments, a plurality of DNA breaks is generated in a target site. In some embodiments, the plurality of DNA breaks comprises two DSBs, two SSBs, or one DSB and one SSB. In some embodiments, each DNA break in the plurality is generated by utilizing a respective gRNA. In some embodiments, introducing more than one DNA break comprises using two different Cas protein, wherein each Cas protein binds to a different gRNA and / or recognizes a different protospacer adjacent motif (PAM). In some embodiments, a CRISPR / Cas system described herein is utilized to insert a sequence provided by an engineered template nucleic acid into a switch (S) region and / or at a location such that the inserted sequence utilizes one or more regulatory sequences located in the immunoglobulin locus (e.g., the µ- Enhancer and / or the µ promoter upstream of Sµ) to express the sequence provided by the engineered template nucleic acid. Non-limiting examples of Cas proteins include Cas9, and variants thereof, and Cas12a, and variants thereof. In some embodiments, a Cas protein is a Cas9 endonuclease or a Cas9 variant, such as a Cas9 nickase. Examples of Cas9 molecules include, without limitation, UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ SpCas9, SaCas9, StCas9, NmCas9, CjCas9, and SpyCas9. In some embodiments, a Cas protein is a Cas12a endonuclease or a Cas12a variant, such as a Cas12a nickase. Examples of Cas12a molecules include, without limitation, AsCas12a, FnCas12a, LbCas12a, PaCas12a, the MAD7™ system (MAD7TM, Inscripta, Inc.), and the Alt-R Cas12a Ultra nuclease (Alt-R® Cas12a Ultra; Integrated DNA Technologies, Inc In some embodiments, a PAM in a target site comprises 3-10 nucleotides in length. In some embodiments, a Cas protein binds to a PAM comprising a sequence of: NGG; NNAGAAW; NNGRRT; NNNNGATT; NVNDCCY; BRTTTTT; NR(A or G)TTTT; NNAAAR(G or A); N(N or A)G; NAAN; NAAAAY; NHDTCCA; NNNVRYM; NNNNRYAC; NAA; GNNNNCNNA; NNGTGA; NNNNGTA; NNGGG; NNNCAT; NNRHHHY; NRRNAT; NNNNCNAA; NNNNCMCA; NNNNCRAA; NNNNGMAA; NNNCC; NGGNG; NNNNCNDD; NYAAA; NRGNN; N(C or D)GGN(T or A or G or C)NN; NRTAW; N(C or K or A)AARC; NAAAG; NV(A or G or C)R(A or G)ACCN; NNGAC; NATGNT; N(T or V)NTAAW(A or T); NNGW(A or T)AY(T or C); NCAA(H(Y or A)B(Y or G); NH(T or C or A)AAAA; NNNATTT; NATAWN(A or T or S); NATARCH; B(T or G or C)GGD(A or T or G)TNN; N(G or T or M)GGAH(T or A or C)N(A or C or K)N; NRG; N(B or A)GG; NGGD(A or K)W(T or A); N(T or C or R)AGAN(A or K or C)NN; NGGD(A or T or G)H(T or M); NGGDT; NGGD(A or T or G)GNN; NNGTAM(A or C)Y; NNGH(W or C)AAA; NTGAR(G or A)N(A or Y or G)N(Y or R); NNGAAAN; NNGAD; NHARMC; NNAAAG; NHGYNAN(A or B); NNAGAAA; NHAAAAA; NH(T or M)AAAAA; NHGYRAA; NNAAACN; NN(H or G)D(A or K)GGDN(A or B); NNNNCTA; NNNNCVGAA; NNNNGYAA; NNNNATN(W or S)ANN; NNWHR(G or A)TA(not G)AA; YHHNGTH; NNNNCDAANN; NNNNCTAA; N(C or D)NNTCCN; NNNNCCAA; NAGRGN(T or V)N(T or C); NNAH(T or M)ACN; CN(C or W or G)AV(A or S)GAC; NAR(G or A)H(W or C)H(A or T or C)GN(C or T or R); NAGNGC; NATCCTN; NGTGANN; HGCNGCR; NAR(A or G)W(T or A)AC; N(C or D)M(A or C)RN(A or B)AY(C or T); NNNCAC; BGGGTCD; NNRRCC; NRRNTT; KARDAT; BRRTTTW; NARNCCN; NAR(A or G)TC; NAAN(A or T or S)RCN; HHAAATD; NNNNGNA; TTV; TTTV; YYV; KKYV; TTTM; TTYV; TTTN; TTTTA; TTN; BTTV; YTV; YTN; NYTV; DTTD; ATTN; RTTNT; HATT; ATTW; RTTN; TVT; TG; TN; TR; TA; TTCN; TTAT; TTTR; TTR; YTTR; YTTN; CTT; TTC; CCD; RTR; VTTR; TBN; VTTN; NGTT; CGTT; AGG; CGG; GTT; or RGTG, wherein: “N”^is^any nucleotide or base; “W” is adenine (A) or thymine (T); UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ “R”^is A or guanine (G); “V”^is A, cytosine (C), or G; “Y”^is C or T; “M” is C or A; “K” is G or T; “D” is A, G, or T; “S” is G or C; “B” is C, G, or T; and “H”^is A, C, or T. In some embodiments, a PAM is located in a target site described herein (e.g., an immunoglobulin locus sequence). In some embodiments, a PAM is located 1,000 nucleotides or less (e.g., 1-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-125, 125-150, 150-175, 175-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, or 900-1,000 nucleotides) away from a target site described herein (e.g., an immunoglobulin locus sequence). A gRNA including, but not limited to, an sgRNA, can be utilized in combination with a Cas protein described herein to promote DNA editing. In some embodiments, a gRNA comprises a sequence that hybridizes with a sequence located within or promixal to a target site described herein (e.g., a sequence located in an immunoglobulin heavy chain locus). A sequence that hybridizes to a gRNA and that is “proximal to a target site” refers to a sequence that is located 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 2-7, 7-12, 12-17, 17-22, 22-27, 27- 32, 32-37, 37-42, 42-47, 47-50, 3-8, 8-13, 13-18, 18-23, 23-28, 28-33, 33-38, 38-43, 43-48, 48- 50, 4-9, 9-14, 14-19, 19-24, 24-29, 29-34, 34-39, 39-44, 44-49, 49-50, 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 50-60, 55-65, 60-70, 65-75, 70-80, 75-85, 80-90, 85-95, 90- 100, 95-105, 100-120, 110-130, 120-140, 130-150, 140-160, 150-170, 160-180, 170-190, 180- 200, 190-200, 200-300, 250-350, 300-400, 350-450, 400-500, 450-550, 500-600, 550-650, 600- 700, 650-750, 700-900, 800-1000, 900-1000, or 1000-1100, or more (e.g., 1500, 200, 2500, etc.) nucleotides upstream or downstream of the target site (e.g., a sequence located in an immunoglobulin heavy chain locus). In some embodiments, a sequence in a gRNA that hybridizes with a sequence located within or proximal to a target site (e.g., a sequence located in an immunoglobulin heavy chain locus) comprises 40 nucleotides or less (e.g., a sequence of 10- 20, 10-30, 10-40, 20-30, 20-40, or 30-40 nucleotides). In some embodiments, a sequence in a gRNA that hybridizes with a sequence located within or proximal to a target site (e.g., a sequence located in an immunoglobulin heavy chain locus) comprises 10-35 nucleotides (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides). In some embodiments, a sequence in a gRNA that hybridizes with a sequence located within or proximal to a target site (e.g., a sequence located in an immunoglobulin heavy chain locus) comprises at least 15 nucleotides (e.g., 15-18, 18-20, 20-22, or 22-24 nucleotides) that are 100% reverse complementary to the sequence in the target site. In some embodiments, a sequence in a gRNA UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ that hybridizes with a sequence located within or proximal to a target site (e.g., a sequence located in an immunoglobulin heavy chain locus) comprises one or more mismatches (e.g., 1, 2, 3, 4, 5, or more mismatches, such as insertions, deletions, and / or substitutions) relative to the target sequence. In some embodiments, a Cas protein described herein and / or a gRNA described herein are encoded by a nucleic acid that is contacted with a cell. In some embodiments, a Cas protein and a gRNA are encoded on the same nucleic acid. In some embodiments, a Cas protein and gRNA are encoded on separate nucleic acids. A nucleic acid encoding a Cas protein and / or a gRNA can comprise DNA, RNA, a DNA-RNA hybrid, or can be a modified nucleic acid, such as a chemically modified nucleic acid described herein. In some embodiments, a nucleic acid encoding a Cas protein and / or a gRNA are introduced into a cell by transfection, electroporation, or contacting the cell with a recombinant virus (e.g., a recombinant adeno-associated virus (rAAV) described herein). However, in some embodiments, a Cas protein is introduced into a cell in the form of a protein and / or a gRNA is introduced into a cell as an RNA. For example, in some embodiments, a Cas protein and a gRNA are introduced into a cell as a pre-formed complex, such as by electroporating the cell in the presence of the pre-formed complex. In some embodiments, a gRNA described herein comprises one or more chemical modifications described herein. In some embodiments, a gRNA comprises one or more chemically modified nucleosides and / or one or more sugar-phosphate backbone chemical modifications. In some embodiments, a gRNA comprises one or more phosphorothioate moieties, one or more 2^-O-Me–modifications, one or more 2^-F-modifications, and / or one or more thioPACE moieties. In some embodiments, a gRNA comprises one or more chemical modifications (e.g., chemically modified nucleosides and / or sugar-phosphate backbone modifications) at the 3^ end and / or the 5^ of the gRNA. In some embodiments, a gRNA comprises one or more chemical modifications (e.g., chemically modified nucleosides and / or sugar-phosphate backbone modifications) that are located internally relative to the the 3^ end and the 5^ of the gRNA (e.g., wherein the gRNA comprises one or more chemical modifications located in a sequence hybridizes with a sequence within or proximal to a target site as described herein). Vectors UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ Other aspects of the present disclosure relate to vectors encoding any of the engineered template nucleic acids or transgenes described herein. In some embodiments, the engineered template nucleic acids are provided to a cell and expressed off of a vector. In some embodiments, expressing a sequence comprised in a vector described herein produces an RNA (e.g., an mRNA) comprising an engineered template nucleic acid described herein. In some embodiments, an RNA comprising an engineered template nucleic acid is encoded by a sequence in a vector which lacks one or more regulatory sequences that promote translation of the RNA into a protein. In some embodiments, a vector comprises deoxyribonucleotides. In some embodiments, a vector comprises ribonucleotides. In some embodiments, a vector comprises both deoxyribonucleotides and ribonucleotides. In some embodiments, a vector is single-stranded. In some embodiments, a vector is double-stranded. In some embodiments, a vector is circular (e.g., circular plasmids, nanoplasmids, and minicircle plasmids). In some embodiments, a vector is linear. In some embodiments, vectors are self-complementary. In some embodiments, a vector is a plasmid, cosmid, or artificial chromosome. In some embodiments, a vector may be maintained in high levels in a cell using a selection method, such as one involving an antibiotic resistance gene. In some embodiments, a vector may comprise a partitioning sequence which ensures stable inheritance of the vector. In some embodiments, a vector is a high copy number vector. In some embodiments, a vector becomes integrated into the genome of a cell. In some embodiments, a vector is provided as a recombinant viral genome. The term “recombinant viral genome” refers to any nucleic acid species heterologous to the natural virus (e.g., a sequence heterologous to an adeno-associated virus (AAV) may comprise an engineered template nucleic acid flanked by AAV ITRs). In some embodiments, a vector comprising any of the engineered template nucleic acids or transgenes described herein is a recombinant viral genome within a recombinant adeno-associated virus (rAAV) particle. In some embodiments, a vector comprising any of the engineered template nucleic acids or transgenes described herein is a recombinant viral genome within a lentivirus particle. In some embodiments, an engineered template nucleic acid comprises at least one other viral genetic sequence. Examples of viral genetic sequence that may be found in viral genomes include, but are not limited to, U3, U5, Tat- binding sequences, LTRs, ITRs, trans-activating response elements, central polypurine tracts, and Psi (^) packaging sequences. UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ In some embodiments, a recombinant viral genome comprising a vector is sufficiently small to be effectively packaged in an AAV viral particle (e.g., the vector has a packaging capacity from 1 to 40 kb, for example from 1 to 30 kb, such as from 1 to 20 kb, for example from 1 to 15 kb, such as from 1 to 10, for example from 1 to 8 kb, such as from 2 to 7 kb, for example from 3 to 6 kb, such as from 4 to 5 kb). In order to fit into the AAV viral particle (e.g., an rAAV particle), in some embodiments, an engineered nucleic acid comprising any of the engineered template nucleic acids, transgenes, or vectors described herein comprises one or more truncated and / or recombinant sequences, as described elsewhere herein. In some embodiments, a truncated and / or recombinant sequence is typically shorter than 4 kb but can be between around 20 bases long and around 2,000 bases long to provide space for other components (e.g., exons, regulatory sequences, other introns, viral packaging sequences) in the nucleic acid (e.g., recombinant gene) construct. In some embodiments, a truncated and / or recombinant sequence is shorter than 4 kb, shorter than 3 kb, or shorter than 2 kb. In some embodiments, a vector comprising an engineered template nucleic acid or transgene thereof comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to any one of the nucleotide sequences set forth in Tables 1-6 (e.g., any one of SEQ ID NOs: 3-4 or 7-29) or a reverse complement thereof. In some embodiments, the vector comprises any one of the nucleotide sequences set forth in Tables 3-6 (e.g., any one of SEQ ID NOs: 3-47-25, or 27-29). In some embodiments, vectors and rAAV particles (e.g., a vector or rAAV particles comprising an engineered template nucleic acid described herein) comprises a portion, or all of, any one of the sequences set forth in Table 6. Table 6. Examples of Vectors for Engineered Template Nucleic Acid Delivery UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ MT83 plasmid: F10-antiALFA nanobody plasmid for mRNA production UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ Recombinant Adeno-Associated Viruses Other aspects of the present disclosure relate to recombinant adeno-associated virus (rAAV) particles comprising engineered template nucleic acids (e.g., transgenes comprising the engineered template nucleic acid). The term “AAV” is an abbreviation for adeno-associated virus. The abbreviation “rAAV” refers to a recombinant adeno-associated virus which is an AAV comprising a polynucleotide sequence not of AAV origin (e.g., an engineered template nucleic acid described herein which is flanked by AAV ITRs). In some embodiments, the polynucleotide (e.g., an rAAV genome described herein) comprises, in relative order, a first AAV ITR, an engineered template nucleic acid, and a second AAV ITR, wherein the engineered template nucleic acid comprises, in relative order, a first homology arm, a heterologous nucleic acid, a second homology arm. In some embodiments, the polynucleotide comprises one or more regulatory sequences described herein which is located between the first and second AAV ITRs (e.g., a regulatory sequence in the heterologous nucleic acid of the engineered template nucleic acid, such as for the purpose of UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ inserting the regulatory sequence in a target site, and / or a regulatory sequence operably linked to the engineered template nucleic acid, such as for the purpose of promoting transcription of the engineered template nucleic acid in a cell). In some embodimens, the polynucleotide comprises one or more sequences encoding an amino acid sequence that regulates a pepetide or protein (e.g., by regulating the stability, trafficking, and / or post-translational modification of the peptide or protein) as described herein. The term “rAAV particle” refers to a viral particle comprising at least one AAV capsid protein and an encapsidated polynucleotide (e.g., a transgene comprising an engineered template nucleic acid described herein flanked by AAV ITRs). In some embodiments, an rAAV genome described herein may be packaged into a capsid and administered to a subject and / or delivered to a selected target cell. In some embodiments, rAAV genomes comprise a nucleic acid (e.g., a vector) comprising an engineered template nucleic acid which is flanked by 5' and 3' AAV inverted terminal repeats (ITRs). In some embodiments, rAAV genomes comprise a transgene flanked by AAV ITRs, wherein the transgene comprises an engineered template nucleic acid operably linked to one or more regulatory sequences. In some embodiments, the 5' and 3' ITRs may be alternatively referred to as “first” and “second” ITRs, respectively. In some embodiments, inverted terminal repeat (ITR) sequences are about 145 bp in length. While the entire sequences encoding the ITRs are commonly used in engineering rAAVs, in some embodiments, some degree of minor modification of these sequences is permissible. In some embodiments, ITR sequences may be modified (see, e.g., disclosures related to nucleic acid engineering and rAAV engineering in: texts such as Sambrook et al., Molecular Cloning. A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, New York (1989); and K. Fisher et al., J Virol., 70:520532 (1996)). The rAAV particles comprising an engineered template nucleic acid disclosed herein, may be of any AAV serotype, including any derivative or pseudotype (e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV2 / 1, AAV2 / 5, AAV2 / 8, AAV2 / 9, AAV3 / 1, AAV3 / 5, AAV3 / 8, AAV3 / 9, or AAV-DJ). As used herein, the serotype of an rAAV refers to the serotype of the capsid proteins of the recombinant virus. Non-limiting examples of derivatives, pseudotypes, and / or other vector types include, but are not limited to, AAVrh.10, AAVrh.74, AAV2 / 1, AAV2 / 5, AAV2 / 6, AAV2 / 8, AAV2 / 9, AAV2-AAV3 hybrid, AAVhu.14, AAV3a / 3b, AAVrh32.33, AAV-HSC15, AAV- HSC17, AAVhu.37, AAVrh.8, CHt- UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ P6, AAV2.5, AAV6.2, AAV2i8, AAV-HSC15 / 17, AAVM41, AAV9.45, AAV6(Y445F / Y731F), AAV2.5T, AAV-HAE1 / 2, AAV clone 32 / 83, AAVShHIO, AAV2 (Y->F), AAV8 (Y733F), AAV2.15, AAV2.4, AAVM41, AAV-DJ, AAV-DJ / 8, and AAVr3.45. Such AAV serotypes and derivatives / pseudotypes, and methods of producing such derivatives / pseudotypes may be done using any suitable method (see, e.g., disclosures related to nucleic acid engineering and rAAV engineering in: Mol. Ther.2012 Apr;20(4):699- 708. doi: 10.1038 / mt.2011.287. Epub 2012 Jan 24. The AAV vector toolkit: poised at the clinical crossroads. Asokan Al, Schaffer DV, Samulski RJ.). Methods for producing and using pseudotyped rAAV vectors may be done using any suitable approach (see, e.g., disclosures related to nucleic acid engineering and rAAV engineering in: Duan et al, J. Virol., 75:7662-7671, 2001; Halbert et al, J. Virol., 74:1524-1532, 2000; Zolotukhin et al, Methods, 28:158-167, 2002; and Auricchio et al., Hum. Molec. Genet., 10:3075-3081, 2001). In some embodiments, the rAAV particles are produced by transfecting a host cell with a a nucleic acid (e.g., a vector comprising an engineered template nucleic acid flanked by AAV ITRs) to be packaged into rAAV particles, and at least one AAV helper nucleic acid (e.g., a helper vector) or packaging nucleic acid (e.g., packaging vector). In some embodiments, the components to be cultured in the host cell to package an rAAV genome in an AAV capsid may be provided to the host cell in trans. Alternatively, in some embodiments, any one or more of the required components (e.g., AAV rep sequences, AAV cap sequences, and / or helper nucleic acid) may be provided by a stable host cell which has been engineered to contain one or more of the required components. In some embodiments, such a stable host cell will contain the required component(s) under the control of either an inducible promoter or a constitutive promoter. Examples of suitable inducible and constitutive promoters are provided herein in the discussion of regulatory sequences. In some embodiments, a helper nucleic acid and a packaging nucleic acid are both used. In some embodiments, rAAV particles comprising an engineered template nucleic acid may be produced using the triple transfection method (described in detail in U.S. Pat. No.6,001,650). The helper nucleic acid and the packaging nucleic acid support AAV replication. In some embodiments, the helper nucleic acid and the packaging nucleic acid support functions, such as activation of AAV gene transcription, stage specific AAV mRNA splicing, AAV DNA replication, synthesis of capsid expression products, and AAV capsid assembly. In some UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ embodiments, a “helper nucleic acid” comprises one or more of an E1 gene, an E2A gene, an E4 gene, and a VA gene. In some embodiments, a helper nucleic acid comprises a vector. Preferably, the helper nucleic acid supports efficient AAV vector production without generating any detectable wild-type AAV particles (e.g., AAV particles containing functional rep and capsid protein genes). In some embodiments, a helper nucleic acid is a helper virus nucleic acid comprising one or more of an E1 gene, an E2A gene, an E4 gene, or an VA gene. In some embodiments, a helper virus, or a recombinant version thereof, comprising a helper nucleic acid is used to transduce a host cell during rAAV particle production. In some embodiments, a “packaging nucleic acid” comprises AAV rep and AAV capsid protein gene sequences. In some embodiments, a packaging nucleic acid comprises a vector. The methods used to construct any embodiment of this disclosure include genetic engineering, recombinant engineering, and synthetic techniques (see, e.g., disclosures related to nucleic acid engineering and rAAV engineering in: Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y). Similarly, methods of generating rAAV particles have been previously described (see, e.g., disclosures related to nucleic acid engineering and rAAV engineering in: K. Fisher et al., J. Virol., 70:520-532 (1993) and U.S. Pat. No.5,478,745). Helper nucleic acids, and methods of making said nucleic acids, have been previously described and are commercially available (see, e.g., information related to rAAV production and nucleic acids that can be utilized to produce rAAV particles in: pDM, pDG, pDP1rs, pDP2rs, pDP3rs, pDP4rs, pDP5rs, pDP6rs, pDG(R484E / R585E, and pDP8.ape plasmids from PlasmidFactory, Bielefeld, Germany; other products and services available from Vector Biolabs, Philadelphia, PA; Cellbiolabs, San Diego, CA; Agilent Technologies, Santa Clara, Ca; and Addgene, Cambridge, MA; pxx6; Grimm et al. (1998), Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors, Human Gene Therapy, Vol.9, 2745-2760; Kern, A. et al. (2003), Identification of a Heparin-Binding Motif on Adeno-Associated Virus Type 2 Capsids, Journal of Virology, Vol.77, 11072-11081.; Grimm et al. (2003), Helper Virus-Free, Optically Controllable, and Two-Plasmid-Based Production of Adeno-associated Virus Vectors of Serotypes 1 to 6, Molecular Therapy, Vol.7, 839-850; Kronenberg et al. (2005), A Conformational Change in the Adeno-Associated Virus Type 2 Capsid Leads to the Exposure of Hidden VP1 N Termini , Journal of Virology, Vol.79, 5296- UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ 5303; and Moullier, P. and Snyder, R.O. (2008), International efforts for recombinant adenoassociated viral vector reference standards, Molecular Therapy, Vol.16, 1185-1188). Methods Methods of B Cell and Immunoglobulin Engineering Other aspects of the present disclosure relate to methods of genetically modified B cells. In some embodiments, a B cell, or cell population thereof, is genetically modified to comprise an engineered Ig using a method comprising contacting a B cell, or cell population thereof, with an engineered template nucleic acid described herein. In some embodiments, an engineered template nucleic acid is provided in a transgene, vector, recombinant viral genome, or rAAV particle described herein. In some embodiments, genetically modified B cells are produced by contacting a B cell, or cell population thereof, with a plurality (e.g., two, three, four, or more) of engineered template nucleic acids. In some embodiments, the B cell, or cell population thereof, are human or mouse B cells. In some embodiments, the B cell, or cell population thereof, is obtained from a subject. In some embodiments, the B cell, or cell population thereof, is autologous to the subject. In some embodiments, the subject comprises a disease, disorder, or condition described herein. In some embodiments, a B cell, or cell population thereof, is obtained from an allogenic donor. In some embodiments, the B cell, or cell population thereof, used in the genetic modification methods described herein are murine lymphoma B-cells. In some embodiments, the murine lymphoma B-cells are derived from the CH12-F3 cell line. In some embodimens, methods of genetically modifying a B cell, or cell population thereof, further comprise electroporation or transfection. In some embodiments, B cells are electroprated or transfected before, during, and / or after being contacted with an engineered template nucleic acid described herein. In some embodiments, the method further comprises contacting a B cell, or cell population thereof, with one or more agents that stimulate CSR. In some embodiments, the one or more agents is contacted with a B cell, or cell population thereof, before, during, or after contacting the B cell, or cell population thereof, with an engineered template nucleic acid. In some embodiments, an agent that stimulates CSR generates an active S region. In some embodiments, an agent that stimulates CSR induces B cell proliferation.In some embodiments, UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ an agent that stimulates CSR is produced by a cell of a feeder cell, which has been co-cultured with one or more B cells (e.g., 3T3 / 40L, 3T3 / BAFF, or 3T3 feeder cells; see , e.g., disclosures related to feeder cells in Nojima et al. (2011). In-vitro derived germinal centre B cells differentially generate memory B or plasma cells in vivo. Nature Communications, 2, Article number 465). In some embodiments, the one or more agents that stimulate CSR is one or more of anti-CD40, CD40L, TGF-^1, IL-4, IL-5, IFN^, IL-10, bacterial lipopolysaccharide (LPS), retinoic acid (RA), B-cell activating factor (BAFF),^anti-^ mAb, and / or anti-CD180.. In some embodiments, one or more agents that stimulate CSR are used to generate an active S region in a B cell, or cell population thereof. In some embodiments, one or more agents that stimulate CSR are contacted with a B cell, or cell population thereof, to generate an active human S^ region, human S^3 region, human S^1 region, human S^1 region, human S^2 region, human S^4 region, or human S^ region. In some embodiments, one or more agents that stimulate CSR are contacted with a B cell, or cell population thereof, to generate an active mouse S^ region, mouse S^3 region, mouse S^1 region, mouse S^2b region, mouse S^2^ region, mouse S^ region, or mouse S^ region. In some embodiments, B cells contacted with LPS and IL-4 comprises active S^ and S^1regions. In some embodiments, B cells contacted with anti-CD40, TGF-^1, and IL-4 comprises active S^ and S^ regions. In some embodiments, one or more mouse B cells are contacted with one or more agents described herein (e.g., one agent or two, three, four, five, six, seven, or more than seven agents), such as anti-CD40 (or CD40L) and IL-4 or LPS and IL-4 (e.g., to induce transcription of a region(s) involved in IgG1 production and / or IgE production), RA and IL-4 and TGFb1 and IL-5 and LPS and BAFF (e.g., to induce transcription of a region(s) involved in IgA production), LPS and IFN-^ (e.g., to induce transcription of a region(s) involved in IgG2a production), or LPS (e.g., to induce transcription of a region(s) involved in IgG3 production). In some embodiments, one or more human B cells are contacted with one or more agents described herein (e.g., one agent or two, three, four, five, six, seven, or more than seven agents), such as CD40L and IL-4 and IL-13 (e.g., to induce transcription of a region(s) involved in IgG4 and / or IgE production), CD40L and IL-10 (e.g., to induce transcription of a region(s) involved in IgG1 and / or IgG3 production), or CD40L and IL-10 and TGF-^ (e.g., to induce transcription of a region(s) involved in IgA1 and / or IgA2 production). In some embodiments, the concentration of LPS that is contacted with one or more B cells is 10-50 ug / mL. In some embodiments, the concentration of IL-4 that is contacted with one or more B cells is 5-30 ng / mL. In some UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ embodiments, the concentration of anti-CD180 that is contacted with one or more B cells is 1-8 ug / mL. In some embodiments, the concentration of TGF^1 that is contacted with one or more B cells is 0.1-1 ng / mL. In some embodiments, the concentration of anti-CD40 that is contacted with one or more B cells is 5-30 ng / mL. In some embodiments, the concentration of RA that is contacted with one or more B cells is 5-20 nM. In some embodiments, the concentration of IL-5 that is contacted with one or more B cells is 5-20 ng / mL In some embodiments, the concentration of BAFF that is contacted with one or more B cells is 5-50 ng / mL. In some embodiments, the concentration of anti-^ mAb that is contacted with one or more B cells is 25- 500 ng / mL. In some embodiments, two or more CSR stimulating agents are contacted with one or more B cells, wherein the two or more CSR stimulating agents comprise: 10-50 ug / mL LPS and 5-30 ng / mL IL-4; 10-50 ug / mL LPS, 5-30 ng / mL IL-4, and 1-8 ug / mL anti-CD180; 10-50 ug / mL anti-CD40 and 5-30 ng / mL IL4; 0.5-2 ug / mL anti-CD40, 5-30 ng / mL IL-4, and 0.1-1 ng / mL TGF^1; 5-20 nM RA, 5-25 ng / mL IL-4, 0.1-20 ng / uL TGF^1, 5-20 ng / mL IL-5, 5-50 ug / mL LPS, and 5-50 ng / mL BAFF; or 10-50 ug / mL LPS, 5-30 ng / mL IL-4, and 25-500 ng / mL anti-^ mAb / dex. In some embodiments, the method further comprises sorting the genetically engineered B cells. In some embodiments, sorting comprises subjecting the cells to flow cytometry. In some embodiments, flow cytometry comprises fluorescent-activated cell sorting (FACS). In some embodiments, the genetically engineered B cell is expanded in vitro to produce a cell population comprising a plurality of modified B cells. In some embodiments, the genetically engineered B cell, or cell population thereof, is administered to a subject. In some embodiments, the genetically modified B cell, or cell population thereof, is engineered in a subject in a method comprising administering to the subject an rAAV particle comprising an engineered template nucleic acid using any of the administration methods described herein. In some embodiments, genetically modified B cells produced using the methods described herein express one or more engineered Igs (e.g., an engineered Ig encoded by an immunoglobulin heavy chain sequence which has been edited using an engineered template nucleic acid described herein, such as an engineered Ig comprising a sequence located in the heterologous nucleic acid of the engineered template nucleic acid). In some embodiments, the engineered Ig produced by the methods described herein is an engineered variant of human IgM, UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ IgD, IgG3, IgG1, IgA1, IgG2, IgG4, IgE, or IgA2. In some embodiments, the engineered Ig produced by the methods described herein is an engineered variant of mouse IgM, IgD, IgG3, IgG1, IgG2b, IgG2a, IgE, or IgA. In some embodiments, an engineered Ig comprises a modified immunoadhesin, such as an Fc-fusion protein. In some embodiments, an engineered Ig comprises the antigen-binding domain of an Fc-fusion protein (e.g., domains 1 and 2 human CD4, TNF domains) or the whole Fc-fusion protein (e.g., Embrel, CD4-IgG2, or CD4-IgG1). In some embodiments, an engineered Ig comprises an LFA3-IgG1 fusion protein or an TNFR-IgG1 fusion protein. In some embodiments, an engineered Ig comprises a second recognition domain at the elbow region of an Ig or a fragment thereof. In some embodiments, an engineered Ig comprises sequences a genetically engineered variable domain. In some embodiments, an engineered Ig is purified from a genetically engineered B cell expressing said engineered Ig. In some embodiments, purification comprises affinity chromatography, ion exchange chromatography, size-exclusion chromatography, or any combination thereof. In some embodiments, an engineered Ig is evaluated using immunohistochemistry, immunofluorescence, mass spectrometry, western blot, enzyme-linked immunosorbent assay (ELISA), or any combination thereof. Methods of Administration and Treatment ^ In other aspects, the present disclosure relates to methods of treating or preventing a disease, disorder, or condition in a subject using any of the engineered template nucleic acids, transgenes, vectors, recombinant viral genomes, rAAV particles, genetically engineered B cells, or a cell population thereof, genetically engineered immunoglobulins, and / or compositions thereof described herein. The terms “treatment,” “treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease described herein. In some embodiments, treatment may be administered after one or more signs or symptoms of the disease have developed or have been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of the disease. For example, treatment may be administered to a susceptible subject prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of exposure to a pathogen). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence. UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ A “subject” to which administration is contemplated refers to a human (e.g., male or female of any age group, e.g., pediatric subject (e.g., infant, child, or adolescent) or adult subject (e.g., young adult, middle-aged adult, or senior adult)) or non-human animal. In certain embodiments, the non-human animal is a mammal (e.g., primate (e.g., cynomolgus monkey or rhesus monkey), commercially relevant mammal (e.g., cattle, rat, mouse, pig, horse, sheep, goat, cat, or dog), or bird (e.g., commercially relevant bird, such as chicken, duck, goose, or turkey)). In certain embodiments, the non-human animal is a fish, reptile, or amphibian. The non-human animal may be a male or female at any stage of development. The non-human animal may be a transgenic animal or genetically engineered animal. The term “patient” refers to a human subject in need of treatment of a disease. The term “subject in need thereof” refers to a human subject having, at risk of having, at once had, or is suspected of having a disease or disorder. In some embodiments, treating a subject in need thereof using any of the methods of the present disclosure comprises administering a therapeutically effective amount of a therapeutic agent provided as any of the engineered template nucleic acids, transgenes, vectors, recombinant viral genomes, rAAV particles, genetically engineered B cells, or cell population thereof, genetically engineered immunoglobulins, and / or compositions thereof described herein. A “therapeutically effective amount” of a therapeutic agent described herein is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition. A therapeutically effective amount means an amount of therapeutic agent (e.g., engineered template nucleic acid, or an rAAV particle or lipid nanoparticle comprising an engineered template nucleic acid), alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms, signs, or causes of the condition, and / or enhances the therapeutic efficacy of another therapeutic agent. In some embodiments, administration of any of the engineered template nucleic acids, transgenes, vectors, recombinant viral genomes, rAAVs, genetically engineered B cells, or cell population thereof, genetically engineered immunoglobulins, and / or compositions thereof described herein achieves one, two, three, four, or more of the following effects, including, for example: (i) reduction or amelioration the severity of disease, disorder, or condition or symptom associated therewith; (ii) reduction in the duration of a symptom associated with a disease, UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ disorder, or condition; (iii) protection against the progression of a disease or disorder or symptom associated therewith; (iv) regression of a disease, disorder, or condition or symptom associated therewith; (v) protection against the development or onset of a symptom associated with a disease, disorder, or condition; (vi) protection against the recurrence of a symptom associated with a disease; (vii) reduction in the hospitalization of a subject; (viii) reduction in the hospitalization length; (ix) an increase in the survival of a subject with a disease; (x) a reduction in the number of symptoms associated with a disease, disorder, or condition; (xi) an enhancement, improvement, supplementation, complementation, or augmentation of the prophylactic or therapeutic effect(s) of another therapy. In some embodiments, administration of any of the engineered template nucleic acids, transgenes, vectors, recombinant viral genomes, rAAV particles, genetically engineered immunoglobulins, genetically modifie B cells, or cell population thereof, and / or compositions described herein is performed subcutaneously, intraocularly, intravitreally, parenterally, subcutaneously, intravenously, intracerebro-ventricularly, intramuscularly, intracranially, intrathecally, orally, intraperitoneally, or by oral or nasal inhalation, or by direct injection to one or more cells, tissues, or organs. In some embodiments, direct injection is performed concurrently with a surgical procedure or interventional procedure. In general, the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract), and / or the condition of the subject (e.g., whether the subject is able to tolerate oral administration, injection, etc.). In some embodiments, compositions are administered to a subject through only one administration route. In some embodiments, multiple administration routes may be exploited (e.g., serially, or simultaneously) for administration of the composition to a subject. In some embodiments, the subject has, is suspected of having, or at risk of developing a disease or disorder selected from the group consisting of cancer, an autoimmune disease, or an infection with a pathogen. The term “cancer” refers to a class of diseases characterized by the development of abnormal cells that proliferate uncontrollably and have the ability to infiltrate and destroy normal body tissues (see, e.g., disclosures related to cancers in Stedman’s Medical Dictionary, 25th ed.; Hensyl ed.; Williams & Wilkins: Philadelphia, 1990). Exemplary cancers which can be treated according to a method described herein include, but are not limited to, acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g., UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (e.g., meningioma, glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma); bronchus cancer; carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma); choriocarcinoma; chordoma; craniopharyngioma; colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma); connective tissue cancer; epithelial carcinoma; ependymoma; endotheliosarcoma (e.g., Kaposi’s sarcoma, multiple idiopathic hemorrhagic sarcoma); endometrial cancer (e.g., uterine cancer, uterine sarcoma); esophageal cancer (e.g., adenocarcinoma of the esophagus, Barrett’s adenocarcinoma); Ewing’s sarcoma; ocular cancer (e.g., intraocular melanoma, retinoblastoma); familiar hypereosinophilia; gall bladder cancer; gastric cancer (e.g., stomach adenocarcinoma); gastrointestinal stromal tumor (GIST); germ cell cancer; head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma), throat cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer)); hematopoietic cancers (e.g., leukemia such as acute lymphocytic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myelocytic leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL)); lymphoma such as Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkin lymphoma (NHL) (e.g., B-cell NHL such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma), follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphomas (e.g., mucosa-associated lymphoid tissue (MALT) lymphomas, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (i.e., Waldenström’s macroglobulinemia), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma and primary central nervous system (CNS) lymphoma; and T-cell NHL such as precursor T- lymphoblastic lymphoma / leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sezary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy type T-cell lymphoma, UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ subcutaneous panniculitis-like T-cell lymphoma, and anaplastic large cell lymphoma); a mixture of one or more leukemia / lymphoma as described above; and multiple myeloma (MM)), heavy chain disease (e.g., alpha chain disease, gamma chain disease, mu chain disease); hemangioblastoma; hypopharynx cancer; inflammatory myofibroblastic tumors; immunocytic amyloidosis; kidney cancer (e.g., nephroblastoma a.k.a. Wilms’ tumor, renal cell carcinoma); liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma); lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung); leiomyosarcoma (LMS); mastocytosis (e.g., systemic mastocytosis); muscle cancer; myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a. myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)); neuroblastoma; neurofibroma (e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis); neuroendocrine cancer (e.g., gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoid tumor); osteosarcoma (e.g.,bone cancer); ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer (e.g., pancreatic andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors); penile cancer (e.g., Paget’s disease of the penis and scrotum); pinealoma; primitive neuroectodermal tumor (PNT); plasma cell neoplasia; paraneoplastic syndromes; intraepithelial neoplasms; prostate cancer (e.g., prostate adenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland cancer; skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)); small bowel cancer (e.g., appendix cancer); soft tissue sarcoma (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma); sebaceous gland carcinoma; small intestine cancer; sweat gland carcinoma; synovioma; testicular cancer (e.g., seminoma, testicular embryonal carcinoma); thyroid cancer (e.g., papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC), medullary thyroid cancer); urethral cancer; vaginal cancer; and vulvar cancer (e.g., Paget’s disease of the vulva). An “autoimmune disease” refers to a disease arising from an inappropriate immune response of the body of a subject against substances and tissues normally present in the body. In other words, the immune system mistakes some part of the body as a UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ pathogen and attacks its own cells. This may be restricted to certain organs (e.g., in autoimmune thyroiditis) or involve a particular tissue in different places (e.g., Goodpasture’s disease which may affect the basement membrane in both the lung and kidney). Exemplary autoimmune diseases which can be treated according to a method described herein include, but are not limited to, glomerulonephritis, Goodpasture’s syndrome, necrotizing vasculitis, lymphadenitis, peri- arteritis nodosa, systemic lupus erythematosis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, systemic sclerosis, dermatomyositis / polymyositis, anti-phospholipid antibody syndrome, scleroderma, pemphigus vulgaris, ANCA-associated vasculitis (e.g., Wegener’s granulomatosis, microscopic polyangiitis), uveitis, Sjogren’s syndrome, Crohn’s disease, Reiter’s syndrome, ankylosing spondylitis, Lyme disease, Guillain-Barré syndrome, Hashimoto’s thyroiditis, and cardiomyopathy. Examples of infectious human pathogens which can be treated according to a method described herein include a virus (e.g., a virus selected from the family of Adenoviridae, Picornaviridae, Herpesviridae, Hepadnaviridae, Coronaviridae, Flaviviridae, Retroviridae, Orthomyxoviridae, Paramyxoviridae, Papovaviridae, Polyomavirus, Poxviridae, Rhabdoviridae, and Togaviridae), a bacteria (e.g., a bacteria selected from the group of Mycobacterium tuberculosis, Streptococcus, Pseudomonas, Shigella, Campylobacter, and Salmonella, a fungus species such as Candida, Aspergillus, Cryptococcus, Histoplasma, Pneumocytis, Stachybotrus, Bacillus anthracis, Clostridium botulinum, Mycobacterium leprae, Yersinia pestis, Rickettsia prowazekii, Bartonella spp.), or another organism, such as a parasite (e.g., a parasite that causes malaria, amoebiasis, babesiosis, giardiasis, toxoplasmosis, cryptosporidiosis, trichomoniasis, Chagas disease, leishmaniasis, African trypanosomiasis (sleeping sickness), Acanthamoeba keratitis, and primary amoebic meningoencephalitis (naegleriasis)). In some embodiments, the subject has, is suspected of having, or at risk of developing a disease or disorder associated with reduced or eliminated function and / or expression of a peptide or protein. In some embodiments, the subject comprises a mutation (e.g., a deletion of one or more nucleotides, a substitution of one or more nucleotides, and / or an insertion of one or more nucleotides) in a gene encoding a peptide or protein that is implicated in a disease or disorder associated with reduced or elimintated function and / or expression of the peptide or protein (e.g., reduced or eliminated function and / or expression relative to a counterpart cell that lacks the mutation, such as a cell comprising the wild-type gene). Non- limiting examples of mutations that can result in reduced or eliminated function and / or UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ expression of a peptide or protein include mutations that result in a deletion one or more exons, deletions of a gene, splice site disruptions (e.g., disruptions that results in amino acid deletions or amino acid insertions in a domain), missense mutations, frameshifts, and truncations. In some embodiments, the disease or disorder associated with reduced or eliminated function and / or expression of a peptide or protein is a cancer, an autoimmune disease, or an infection with a pathogen described herein. In some embodiments, the disease or disorder associated with reduced or eliminated function and / or expression of a peptide or protein is hemophilia. In some embodiments, the disease or disorder associated with reduced or eliminated function and / or expression of a peptide or protein is Hurler’s syndrome.. In some embodiments, the disease or disorder associated with reduced or eliminated function and / or expression of a peptide or protein is Gaucher’s disease. In some embodiments, the disease or disorder associated with reduced or eliminated function and / or expression of a peptide or protein is Pompe’s disease. In some embodiments, an engineered template nucleic acid described herein (e.g., a nucleic acid comprised in an rAAV described herein, such as an rAAV of serotype AAV-DJ, or comprised in a lipid nanoparticle described herein). In some embodiments, the engineered template nucleic acid comprises the following components: a first homolog arm; a heterologous nucleic acid comprising one or more non-coding sequences (e.g., one or more regulatory sequences) and / or one or more coding sequences; and a second homology arm. In some embodiments, the engineered template nucleic acid comprises the following components: a first homology arm; a promoter (e.g., a core promoter); a signal peptide, a splice acceptor site; a splice donor site; a sequence coding for one or more antigen / target-binding domains; and a second homology arm. In some embodiments, the engineered template nucleic acid is utilized to generate a Fc-fusion protein (e.g., entanercept, also known as Enbrel) described herein and comprises the following components; a first homology arm; a promoter (e.g., a core promoter); a signal peptide; a sequence encoding a TNF receptor 2; a splice donor site; and a second homology arm. In some embodiments, the engineered template nucleic acid is utilized to generate an antimalarial antibody (e.g., wherein the recognition region is at the elbow) described herein and comprises the following components; a first homology arm; a splice acceptor site; a sequence encoding LILRB1 domains 3 and 4; a splice donor site; and a second homology arm. In some embodiments, treating a subject in need thereof as described herein comprises engineering a B cell using any of the methods described herein and then administering the UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ genetically modified cell, or cell population thereof, to the subject. In some embodiments, treating a subject in need thereof comprises contacting a B cell with any of the engineered template nucleic acids, transgenes, vectors, recombinant viral genomes, rAAV particles, and / or compositions thereof described herein, thereby generating a genetically engineered B cell, and subsequently administering the genetically engineered B cell to a subject. In some embodiments, the B cells are obtained from the subject prior to genetic engineering. In some embodiments, the B cells are obtained from an allogenic donor prior to genetic engineering. In some embodiments, treating a subject in need thereof comprises administration of an engineered Ig described herein. Genetically Engineered Cells ^ Other aspects of the present disclosure relate to genetically engineered B cells comprising engineered Igs described herein. In some embodiments, a genetically engineered B cell comprises an engineered Ig is produced by a method described herein. In some embodiments, a genetically engineered B cell comprises an engineered template nucleic acid, a transgene, a vector, or a recombinant viral genome described herein. In some embodiments, a genetically engineered B cell of the present disclosure is expanded after being contacted with an engineered template nucleic acid, a transgene, a vector, a recombinant viral genome, or an rAAV particle described herein, thereby yielding a cell population. In some embodiments, a genetically engineered B cell is a mammalian B cell, such as a B cell from a non-human primate (e.g., cynomolgus monkey or rhesus monkey, etc.), human, rodent (e.g., mouse, rat, etc.), cattle, pig, horse, sheep, goat, cat, or dog In some embodiments, a genetically engineered B cell is a mouse B cell. In some embodiments, a genetically engineered B cell is a human cell. In some embodiments, a genetically engineered B cell is a precursor B cell (e.g., a mouse precursor B cell or a human precursor B cell). In some embodiments, a genetically engineered B cell is an immature B cell (e.g., a mouse immature B cell or a human immature B cell). In some embodiemnts, a genetically engineered B cell is a mature B cell (e.g., a mouse mature B cell or a human mature B cell). Compositions ^ Other aspects of the present disclosure relate to compositions comprising engineered template nucleic acids for in vitro or in vivo B cell engineering. Additionally, compositions UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ comprising engineered B cells obtained by any of the methods described herein are also provided. Accordingly, in some embodiments, a composition may comprise any of the engineered template nucleic acids, transgenes, vectors, recombinant viral genomes, rAAV particles, and / or genetically engineered B cells or cell population thereof described herein. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, a composition comprising an engineered template nucleic acid or a genetically engineered B cell further comprises a liposome, a lipid, a lipid complex, a lipid nanoparticle, a microsphere, a microparticle, a nanosphere, and / or a nanoparticle, or may be otherwise formulated for administration to the cells, biological samples, tissues, organs, or body of a subject in need thereof. In some embodiments, a composition comprising an engineered template nucleic acid or a genetically engineered B cell further comprises a pharmaceutical excipient. In some embodiments, pharmaceutically acceptable excipients (excipients) are substances other than a therapeutic agent that are intentionally included in a drug delivery system. In some embodiments, excipients do not exert or are not intended to exert a therapeutic effect. Excipients may act to a) aid in processing of the drug delivery system during manufacture, b) protect, support or enhance stability, bioavailability or patient acceptability of the API, c) assist in product identification, and / or d) enhance any other attribute of the overall safety, effectiveness, or delivery of the therapeutic agent during storage or use. A pharmaceutically acceptable excipient may or may not be an inert substance. Excipients include, but are not limited to, absorption enhancers, anti-adherents, anti-foaming agents, anti-oxidants, binders, buffering agents, carriers, coating agents, colors, delivery enhancers, delivery polymers, dextran, dextrose, diluents, disintegrants, emulsifiers, extenders, fillers, flavors, glidants, humectants, lubricants, oils, polymers, preservatives, saline, salts, solvents, sugars, suspending agents, sustained release matrices, sweeteners, thickening agents, tonicity agents, vehicles, water-repelling agents, and wetting agents. In some embodiments, a composition comprising an engineered template nucleic acid or a genetically engineered B cell may be a pharmaceutical composition further comprising additional components commonly found in pharmaceutical compositions. Such additional components can include, but are not limited to: anti-pruritics, astringents, local anesthetics, or anti-inflammatory agents (e.g., antihistamine, diphenhydramine). UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ Pharmaceutical compositions of the present disclosure may be suitable for treatment regimens and thereby administered to a subject via a variety of methods described herein. Such compositions may be formulated for use in a variety of therapies, such as, for example, in the amelioration, prevention, and / or treatment of conditions. Accordingly, compositions described herein may be administered to a subject such as human or non-human subjects, a host cell in situ in a subject, a host cell ex vivo, a host cell derived from a subject, or a biological sample (e.g., one derived from a subject). For administration of an injectable aqueous solution, the composition may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline, polyalcohols, or glucose. For example, one dosage of a therapeutic agent may be dissolved in an isotonic NaCl solution and optionally added to a larger volume of hypodermoclysis fluid prior to being injected at the proposed site of infusion. In some embodiments, the composition is provided in a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. A composition may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Kits ^ In some aspects, the disclosure relates to kits comprising any of the engineered template nucleic acids, transgenes, vectors, recombinant viral genomes, rAAV particles, genetically engineered B cells, or cell population thereof, and / or compositions described herein. In some embodiments, the kits described herein may be used, for example, B cell genetic engineering, expression of a genetically engineered immunoglobulin, or treatment of a subject in need thereof according to any of the methods described herein. The kits described herein may include one or more containers housing components for performing the methods described herein, and optionally instructions for use. The components may be prepared sterilely, packaged in a syringe, and shipped refrigerated. Alternatively, they may be housed in a vial or other container for storage. A second container may have other components prepared sterilely. Alternatively, the kits may include the active agents premixed UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ and shipped in a vial, tube, or other container. The kits may also include other components, depending on the specific application, for example, containers, cell media, salts, buffers, reagents, syringes, needles, a fabric, such as gauze, for applying or removing a disinfecting agent, disposable gloves, a support for the agents prior to administration, etc. In some embodiments, may further comprise components needed for inducing uptake of any of the engineered template nucleic acids, transgenes, vectors, recombinant viral genomes, or rAAV particles described herein into a cell. Each component of the kits, where applicable, may be provided in liquid form (e.g., in solution) or in solid form, (e.g., a dry powder). In certain cases, some of the components may be reconstitutable or otherwise processible (e.g., to an active form), for example, by the addition of a suitable solvent or other species (for example, water), which may or may not be provided with the kit. In some embodiments, a kit further comprises a set of instructions for carrying out the methods described herein. As used herein, “instructions” can define a component of instruction and / or promotion, and typically involve written instructions on or associated with packaging of this disclosure. Instructions also can include any oral or electronic instructions provided in any manner such that a user will clearly recognize that the instructions are to be associated with the kit, for example, audiovisual (e.g., videotape, DVD, etc.), Internet, and / or web-based communications, etc. The written instructions may be in a form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals or biological products, which can also reflect approval by the agency of manufacture, use or sale for animal administration. As used herein, “promoted” includes all methods of doing business including methods of education, hospital and other clinical instruction, scientific inquiry, drug discovery or development, academic research, pharmaceutical industry activity including pharmaceutical sales, and any advertising or other promotional activity including written, oral, and electronic communication of any form, associated with this disclosure. Additionally, the kits may include other components depending on the specific application, as described herein. The kits may have a variety of forms, such as a blister pouch, a shrink-wrapped pouch, a vacuum sealable pouch, a sealable thermoformed tray, or a similar pouch or tray form, with the accessories loosely packed within the pouch, one or more tubes, containers, a box, or a bag. The kits may be sterilized after the accessories are added, thereby allowing the individual accessories in the container to be otherwise unwrapped. The kits, or any of its components, can be sterilized UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ using any appropriate sterilization techniques, such as radiation sterilization, heat sterilization, or other sterilization methods known in the art. EXAMPLES Example 1 Nuclease-free genome editing in B cells Engineered Template Nucleic Acid Structure In some embodiments, homology arms are designed so that (1) one of the two DSB ends from S region can anneal to one of the arms, and (2) the inserted sequence is anchored outside of the switch region and thus remains within the heavy chain locus after class-switch recombination (CSR). Therefore, in some embodiments, at least one HA is within or proximal to an active switch region and least one HA is upstream and outside of S^, or downstream and outside of an acceptor S region. In some embodiments, an engineered template nucleic acid is placed in between two ITR sequences of a rAAV genome, so that it is packaged in a rAAV particle during rAAV production. An engineered template nucleic acid contains a first homology arm, a heterologous nucleic acid, and a second homology arm. In some embodiments, it may also be operably linked to a full-length promoter with its enhancer or a core promoter that precedes the left homology arm. In some embodiments, the role of the promoter is to enhance HDR editing efficiency. No meaningful transcript will be produced from this promoter because the heterologous nucleic acid would not contain a Kozak or methionine start codon. Results Homology-dependent insertion of a small DNA fragment into the S regions During CSR, multiple DSBs occur both at Sµ and at a downstream activated S region. Sµ frequently interacts with the 3’ regulatory region (3’RR) downstream of the Igh locus and germline transcription of Sµ is constitutive. Sµ, therefore, is the first target of AID during CSR, resulting in intra-S DSBs that are recombined with themselves. A downstream S region with an activated germline transcript promoter shortly synapses with Sµ at the 3’RR region via chromatin-loop extrusion mechanism, resulting in inter-S recombination and productive class- switching (FIG.1C). UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ In some embodiments, an engineered template nucleic acid could be designed to anneal with DSB ends within Sµ, likely during non-productive intra-S recombination, to facilitate Sµ edit FIG.1D). In some embodiments, an engineered template nucleic acid with a first homology arm (HA) homologous to Sµ and a second HA homologous to Sα could facilitate HDR at Sµ-Sα junction during productive S-region synapsis. HAs were chosen from regions near frequently observed Sµ-Sα junctions found in class- switched CH12-F3 cell line. These homology arms also flank the AID target-rich core S regions. Given that these HAs have fewer AID target motifs, they are more likely to contain DSBs with long ssDNA ends during CSR. These long single-stranded regions arise from resection during mismatch repair (MMR) resolution of a dU-dG mismatch, and the length of the resected 3’ ends is limited by adjacent nicks. Further, the first HA which is 5’ of the core Sµ is less likely to be excised during CSR, allowing inserted genomic material to be retained after recombination. The murine lymphoma B-cell line CH12-F3 robustly undergoes class-switching to IgA when treated with anti-CD40, TGF-β1, and IL-4 (FIG.1E). Utilizing this predictable pattern of CSR, CH12-F3 cells were electroporated with Sµ engineered template nucleic acid or Sα engineered template nucleic acid, each containing a short, unique heterologous nucleic acid flanked by HAs, as depicted in FIG.1D. Electroporated cells were immediately treated with anti- CD40, TGF-β1, and IL-4 to induce IgA class switching. PCR with one primer binding to the tag sequence and the other binding outside of either homology arm was used to detect the site-specific insertion of the tag fragment. PCR products with lengths correlating with predicted homology-based insertions of the heterologous nucleic acid were detected using primers initiating at both the 5’ and 3’ of the Sµ insertion site (FIGs.1F and 1G). These PCR products were not detected in cells that were not electroporated with engineered template nucleic acid. Similarly sized bands were detected in resting cells, which were not incubated with CSR-inducing agents but electroporated with Sµ engineered template nucleic acid, but at lower intensity, consistent with the basal level of germline transcription and low levels CSR (FIG.1F) observed in these cells. Similar PCR results were also observed in cells edited with Sα engineered template nucleic acid (FIGs.1H and 1I). In both Sµ and Sα edits, PCR at the 3’ end of S-regions (Tag-F and Sm-R1 or Tag-F and Sa-R1 primer pairs) yielded unique bands corresponding to the engineered template nucleic acid target-region UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ insertion comprising the heterologous nucleic acid. However, PCR at 5’ region of the edits yielded a few larger PCR products in edited cells, suggesting possible non-specific insertion of the engineered template nucleic acid at the 5’ end or PCR artifacts. Thus, germline transcription and AID activation promoted insertion of genetic material into the Sµ region and at the junction of Sµ and Sα during CSR. CSR facilitates insertion of ALFA tag and LILRB-d3d4 at the BCR elbow region in CH12-F3 cells In some embodiments, a heterologous nucleic acid comprising an exon with flankingSA / SD is inserted at the Sµ region, its transcript can be spliced into the processed heavy-chaintranscript, and the resulting peptide will be positioned at the elbow region linking VDJ and CH1 domains (FIG.2A). In humans, naturally occurring antibodies can contain such elbow constructs, derived from exons expressing parts of the LAIR1 and LILRB1 receptors (FIG.2B). As these natural examples suggest, engineered exon insertions at the Sµ region can have therapeutic utility because they can express new elbow domains which confer a new specificity to the expressed antibody. ALFA-tag (13 amino acids) (FIG.2B) and two LILRB1 constructs detected in malaria- resistant individuals, namely LILRB1-d3d4 (200 aa) and LILRB1-d3 (101 aa), were first tested for their ability to be introduced into murine BCR elbows. Murine transmembrane IgM, IgG1, or IgA containing OKT-3 variable domains and ALFA elbows were overexpressed in Expi293F cells. Antibody constructs with ALFA-elbows were expressed at levels similar to those of unmodified antibodies, suggesting that fusion of ALFA peptide at the elbow domain did not impair antibody folding or expression. These antibody fusions recognize both its cognate antigen, human CD3, and anti-ALFA nanobodies with comparable efficiencies (FIGs.2C and 2D). Similarly, LILRB1-d3d4 was efficiently expressed at IgM elbow region. However, fusion of LILRB1-d3to the elbow ablated antibody expression, possibly due to the lack of flexibility and steric hindrance caused by LILRB1-d3 (FIGs.2E and 2F). ALFA and LILRB1-d3d4 coding sequences were thus included into Sµ and Sα engineered template nucleic acids for CSR-mediated elbow editing (FIGs.3A and 3B). LILRB1- d3d4 heterologous nucleic acid was designed to emulate the insert found in malaria-resistant individuals, flanked by LILRB1 introns 5 and 7. ALFA heterologous nucleic acids contained UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ SA / SD pair from LILRB1 exon 8 and its flanking introns. Each engineered template nucleic acid was incorporated in a rAAV genome vector, preceded by CMV promoter. In CSR-mediated editing experiments, CH12-F3 cells were treated with anti-CD40, TGF-β1, and IL-4 and simultaneously infected with rAAV particles carrying engineered template nucleic acids (FIG. 3C). In the control CRISPR-mediated editing experiment, CH12-F3 cells were electroporated with CRISPR-Cas12a RNP complexes targeting Sµ and Sα, then recovered in growth media and infected with rAAV particle. ALFA and LILRB1 elbows in edited cells were detected by flow cytometry. CSR-mediated editing resulted in ALFA-tag heterologous nucleic acid insertion frequencies that were markedly higher than those of unstimulated samples, up to 0.7%, usingboth ALFA-Sµ and ALFA-Sα templates (FIGs. 3D and 3E). Although CSR-mediated editing isfive- to six-fold less efficient than CRISPR-Cas12a editing, B-cell engraftment studies suggests this efficiency was sufficient to drive expansion of edited B cells in vivo after appropriate immunization. CSR-mediated introduction of LILRB1-d3d4 resulted in somewhat lower numbers of LILRB1-d3d4-expressing BCR; approximately 0.25% of CH12-F3 cells were successfully edited in this way (FIGs.3F and 3G). Thus, DSBs associated with CSR were utilized to introduce novel exons into Sµ region and at the junction of Sµ and -Sα. CSR-mediated editing in murine primary B cells Murine B cells undergo class-switching to IgG1 in vitro when treated with bacterial lipopolysaccharide (LPS) and IL-4. LPS is a potent mitogen, engaging both BCR and Toll-like receptor 4 (TLR-4) and triggering B-cell proliferation at concentrations as low as 0.1 ug / mL. Engagement of these LPS receptors activates nuclear factor κB (NF-κB), which subsequently induces AID expression essential for CSR. Engagement of CD180, a B-cell surface receptor homologous to TLR-4, also induces B cell proliferation. CD180 signaling, however, is distinct from the TLR-4 axis and has been reported to induce CSR only in transitional T1 B cells that constitutively express AID. Approximately 35% of splenic naïve mature B cells isolated from C57BL / 6J mice consistently class-switched to IgG1 when treated with LPS and IL-4, but not with LPS or anti- CD180 alone (FIG.4A). To insert an exon encoding ALFA tag heterologous nucleic acid into Sµ, primary B cells were treated with these three conditions and transduced with rAAV encapsidating ALFA- Sµ engineered template nucleic acid (full procedure shown in FIG.4B). UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ Among these conditions, that which induced highest levels of CSR (LPS and IL-4) also resulted in the highest rate of ALFA elbow expression, up to 0.3%, ten-fold higher than anti-CD180 treatment (FIG.4C). Editing efficiency in cells stimulated with LPS alone was approximately half that observed with LPS and IL-4. As observed in CH12-F3 cells, CSR-induced editing efficiency in primary B cells was approximately eight-fold lower than seen with Cas12a- mediated editing (FIG.4D). The isotype of ALFA+BCR correlates with the proportion of class- switched cells with different treatments. Thus, in LPS and IL-4-activated B cells, more than half of ALFA+BCRs were IgG1, while LPS-treated cells expressed mostly ALFA+IgM (FIG.4E). These approaches used the ALFA-Sµ heterologous nucleic acid with HAs homologous to Sµ alone. Insertion of ALFA heterologous nucleic acid into IgG1 may occur through several mechanisms including switching to IgG1 after ALFA heterologous nucleic acid insertion at Sµ, incorporation of ALFA heterologous nucleic acid into Sµ-Sγ1 junction during S-region synapsis, and non-homologous insertion of ALFA heterologous into DSBs in the transcriptionally active Sγ1 region. To determine the mechanisms by which ALFA tag heterologous nucleic acid was inserted and expressed as part of IgM, the Sµ regions from ALFA+sorted primary B cells were Sanger sequenced. A primer pair priming outside of regions homologous to Sµ HAs was used to amplify full-length edits occurring within Sµ (FIG.5A, “PCR strategy”). To capture diverse editing patterns and minimize the impact of PCR bias, bulk PCR products were resolved on an agarose gel. Similarly sized DNA bands were then excised and purified for cloning and sequencing. The majority of ALFA heterologous nucleic acid-containing sequenced products appeared to be products of successful HDR, with ALFA heterologous nucleic acid inserted in the targeted, engineered template nucleic acid -homologous genomic region. A G >A point mutation introduced in the 5’ HA of the engineered template nucleic acid was also faithfully replicated in the edited genomes (HDR-1 editing pattern). In addition to this designed mutation, a few HDR- patterned PCR products contain a non-templated C>T mutation in the first HA region (HDR-2 editing pattern), or both the C >T mutation and another non-templated A>G mutation within the in6 portion of the ALFA heterologous nucleic acid insert (HDR-2 editing pattern). Several other PCR products show partial insertion of AAV genome at Sµ (ITR-1 editing pattern). The second HA was utilized for site-specific insertion of ALFA heterologous nucleic acid, while the rest of the AAV vector upstream of ALFA heterologous nucleic acids, including a portion of its 5’ ITR, UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ was incorporated within Sµ independently of the first HA. This insertion junction revealed 3-nt microhomology between the Sµ end and the 5’ ITR end. This hybrid editing pattern may be a product of both HDR and MMEJ. FIG.5B quantifies the frequency of each insertion pattern associated with the indicated bands on an agarose gel of PCR products. The majority of sequences isolated from Band B derived from HDR-editing patterns, and no ITR insertions were observed. In contrast, Band A contained roughly equal numbers of complete HDR-edited and ITR-insertion products. No ALFA heterologous nucleic acids insertions were observed in the smaller Band C. Note that sequences that lacked ALFA tag heterologous nucleic acid sequence, despite sorting for this tag, may derive from amplification of the excluded Igh allele. To determine the genomic basis of ALFA+IgG1+cells when only Sµ HA were used, a forward primer binding ALFA heterologous nucleic acid was combined with one of six reverse primers spanning Sγ1 (FIGs.5C-5D, “PCR strategy”). Sequencing of these PCR products revealed diverse recombination patterns at the junction between ALFA heterologous nucleic acid and Sγ1. A commonly observed pattern (“Sµ-HA junction pattern”) included a portion of the second HA joined to a region mid-Sγ1. This pattern suggested that the ALFA heterologous nucleic acid sequence was inserted before CSR to IgG1, likely via HDR. A similar pattern was also observed in a number of sequences, except that intron in7, part of the ALFA heterologous nucleic acid, was deleted to various lengths (“intron 1-3 junction patterns”) consistent with CSR after ALFA heterologous nucleic acid insertion and a recombination between this intron and Sγ1. Note that this G-rich intron appears to be an efficient AID target. However, it cannot be excluded that the 3’ITR was also initially inserted and then deleted by CSR. AAV background genome was observed in other instances of insertion. Recombination with Sγ1 occurred at a stuffer sequence between ALFA heterologous nucleic acid and ITR (“Stuffer junction pattern”) and more often at a hairpin region within 3’ ITR (“ITR-2 junction pattern”). In some cases, short, flipped segments of the ITR were also present at the Sγ1 junctions (“ITR-3 and ITR-3 junction patterns”). Similar ITR insertions into DSBs, where an ITR is truncated and rearranged near its hairpin structures, are commonly reported in studies of AAV integration. Because these junction patterns are similar to insertion patterns in these other studies, it is possibly that the 3’ end of the AAV genome was inserted directly to Sγ1 DSBs UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ during Sµ-Sγ1 synapsis, and the second HA was not used. In several of these patterns, for example Intron-junction pattern 1, microhomologies were observed at the junction, suggesting that both NHEJ and microhomology-mediated end joining (MMEJ) contribute to non-templated recombination with Sγ1. Amplification products from primers Sγ1-R1, -R2, and -R3 contain mostly Sµ-HA and intron junctions, while primers more distal to Cγ1 captured both ITR insertions and intron junctions (FIG.5E). Also, more ITR insertions were observed in sequences of larger bands (1A, 4A, 5A and 6A) than in smaller bands obtained from the same primer pair (1B, 4B, 5B, and 6B). Overall, the frequencies of ITR junctions were lower than Sµ-HA and intron patterns, although PCR biases against longer or GC-rich sequences may result in underrepresentation of ITR- pattern insertions. In general, these sequencing data from CSR-mediated editing of primary B cells with ALFA-Sµ engineered template nucleic acid suggested that both HDR and AAV genome insertion contributed to expression of ALFA tag heterologous nucleic acid at the BCR elbow. They also suggested that Sµ with an inserted ALFA tag heterologous nucleic acid can often recombine with a synapsed S region (Sγ1 in this experiment), enabling ALFA expression in isotypes other than IgM. Designs of homology arms and splice constructs Because both HDR and AAV-insertion contributed to productive ALFA heterologous nucleic acid insertion at S regions, the ability of 3’ HAs to alter the efficiency of HDR or bias the isotype of ALFA+BCRs was analyzed. The contribution of AAV-insertion to the generation of ALFA+BCRs was also analyzed. In primary B cells, varying second homology arms to Sµ or Sγ1 did not change the proportions of IgM and IgG1 isotypes in ALFA+populations or the efficiencies of ALFA heterologous nucleic acid insertion (FIGs.6A and 6B). Removing homology arms in AAV repair templates (ALFA-no HA) reduced editing efficiencies by half to one-third of those of ALFA-Sµ or -Sγ1 engineered template nucleic acids. In contrast, second HAs influenced the isotypes of edited cells in CH12-F3 cells (FIGs. 6A and 6B). Specifically, engineered template nucleic acids with second HA homologous to Sµ (ALFA-Sµ and ALFA-Sµ.v2) resulted in 40% more ALFA+BCR of the IgM isotype than UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ ALFA-noHA templates, while second HA homologous to Sα (ALFA-Sα engineered template nucleic acid) increased the proportion of IgA BCR by 30% compared to ALFA-Sµ (FIG.6D). As with primary cells, the ALFA-noHA templates inserted with about half the efficiency as template nucleic acids with homology arms, suggesting that half of insertions were mediated by HDR. The contribution of the ALFA-tag heterologous nucleic acid intron splice donor and acceptor sites to the efficiency of insertions was investigated. Two splice donor / acceptor pairs were compared: those deriving from exon 8 of LILRB1, used in the preceding experiments, and the Cµ acceptor and the J4 donor sites, essentially duplicating these sites present in the BCR locus. This latter splice pair was more efficient than the LILRB1 pair in both primary B cells and CH12-F3 cells (FIG.6E), suggesting that further optimization of these sites would result in more efficient insertion or more consistent use of the inserted exon. Materials and Methods Plasmids Sµ α engineered template nucleic acids and Sα α engineered template nucleic acids used in FIGs.2A-2E were ordered as gblocks form IDT and cloned into promoter-less Nanoluc plasmid pNL1.2 (Promega). Engineered template nucleic acids comprising ALFA-Sµ, ALFA- Sα, LILRB1-Sµ, LILRB1-Sα, ALFA-Sµ.v2, and ALFA-Sγ1 sequences were ordered as gblocks and cloned into M71.v2 AAV genome vector. OKT-3 variants with ALFA and LILRB1 elbows were cloned into murine OKT-3-IgG2a plasmid. Cell culture and transfection Expi293F cells (Thermo Fisher Scientific, A14527) were maintained in Expi293™ Expression Medium (Thermo Fisher Scientific, A1435102) following the manufacturer’sinstructions. Cells were transfected with FectoPRO® reagent (Polyplus) at 3 million / ml.Human embryonic kidney 293T (HEK293T) cells (ATCC, CRL-1573) were maintained in Dulbecco’s Modified Medium (DMEM, Life Technologies) supplemented with 10% FBS (Sigma-Aldrich), 2 mM Glutamax-I (Life Technologies), 100 µM nonessential amino acids (Life Technologies), and 1 mM sodium pyruvate. Cells were plated to reach 70-80% confluency sixteen to eighteen hours before transfection with AAV expression plasmids for AAV production (described below). UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ Cells were maintained in RPMI 1640 medium supplemented with 10% FBS, 100 ^M Non-Essential Amino Acids (NEAA, Thermo Fisher Scientific), 1 mM sodium pyruvate (Thermo Fisher Scientific), 10 mM HEPES (Thermo Fisher Scientific), and 55 ^M 2- Mercaptoethanol (Thermo Fisher Scientific). AAV production HEK293T cells were seeded in T175 flasks at 70-80% confluency in growth media fourteen to eighteen hours before transfection. Cells were transfected with pHelper (Cell Biolabs), AAV-DJ capsid (Cell Biolabs), and AAV2-genome plasmids, at 15 ug of each plasmid type / flask using Polyethylenimine Hydrochloride “Max” (MW 40,000) (PEI, Polysciences) at a 1:3 plasmid:PEI ratio. Growth media was replaced with production media, formulated similarly to growth media except with 2% FBS. Cells were harvested seventy-two to ninety-six hours post transfection. AAV particles were purified using either AAVPro® Purification Kit, All serotypes (Takara Bio) or POROS™ GoPure™ AAVX pre-packed columns according to manufacturers’ protocols. Titers of the purified particles were determined using AAVPro® Titration Kit for Real Time PCTR v.2 (Takara). Cas12a RNP formation and electroporation crRNAs for Cas12a variants were ordered from IDT. crRNAs were resuspended in IDTE (IDT) and annealed by incubation at 95ºC for five minutes and cooling down at lowest ramp rate in a thermocycler. For each electroporation sample, RNP complexes were formed by mixing 240 pmol of Mb2Cas12a protein with 480 pmol of crRNA in PBS to reach a final volume of 10 µL. The RNP mixture was incubated at room temperature for twenty to thirty minutes, then mixed with 100 µL of cell suspension in electroporation solution. CH12-F3 were electroporated using Lonza 4D module according to Lonza’s protocols. After electroporation, the cells were transferred to growth media containing AAV particles for editing experiments. Mice Nine- to twelve-week-old C57BL / 6J from Jackson Laboratories were used as a source of splenic B cells. All mice were housed and cared at the institutional animal facility in UF Scripps (Jupiter, FL), following the Animal Welfare Act and other federal, state, and local policies and UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ regulations. All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee under the approval protocol number 17-026. Mouse splenic B-cell activation and editing Whole spleens from Nine- to twelve-week-old C57BL / 6J mice were pulverized and mechanically crushed on the inner top of 70 ^m cell strainers in RPMI 1640 medium (Thermo Fisher Scientific, 61870127) with 2% FBS (Thermo Fisher Scientific, 26140-079). After red blood cell lysis in a NH4Cl solution (BD Biosciences, 555899) at room temperature for three minutes, B cells were neutralized with Ca2+ / Mg2+free PBS with 0.5% BSA (Sigma-Aldrich, A1470) and 2 mM EDTA and then isolated using murine B-cell purification kit (Miltenyi Biotec) and LS columns (Miltenyi Biotec). Recovered B cells were maintained in RPMI 1640 medium with 10% FBS, 100 ^M Non-Essential Amino Acids (NEAA, Thermo Fisher Scientific, 11140050), 1 mM sodium pyruvate (Thermo Fisher Scientific, 11360070), 10 mM HEPES (Thermo Fisher Scientific, 15630080), 55 ^M 2-Mercaptoethanol (Thermo Fisher Scientific, 21985023) and appropriate cytokines. In CSR-mediated editing experiments, immediately after infection, isolated B cells were cultured at 1 million / mL and treated with one of these conditions: (1) 30 ^g / ml LPS and 20 ng / ml mouse IL-4; (2) 10 ^g / ml LPS; (3) 5 ^g / ml anti-mouse CD180. Twenty-four hours after cytokine treatment, the cells were infected with rAAV-DJ particles carrying engineered template nucleic acidat 1 million MOI. The cells were analyzed with a flow cytometer or sorted seventy- two and ninety-six hours after cytokine treatment. In CRISPR-Cas12a editing experiments, B cells were activated for twenty-four hours with 5 ^g / ml anti-mouse CD180 antibodies before electroporation with Mb2Cas12 RNP complexes and AAV-DJ infection at 1 million MOI. The cells were analyzed seventy-two and ninety-six hours after anti-mouse CD180 treatment. Staining, flow analysis, and sorting of murine B cells Engineered B cells were collected and washed with Ca2+ / Mg2+ free PBS with 0.5% BSA(Sigma-Aldrich, A1470) and 2 mM EDTA. The cells were first stained with Zombie Red (1:3000, Biolegend) for ten minutes at room temperature and washed, then Fc receptors were blocked with anti-mouse CD16 / CD32 (1:100, BD Biosciences) for ten minutes at room UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ temperature and washed. These cells were then stained with one of the following antibody combinations: anti-mouse IgK-BV786 (1:750, Biolegend), anti-mouse IgM-BV421 (1:100, Biolegend), anti-mouse IgA-PE (1:1500, eBioscience), anti-mouse IgD-BV711 (1:800, Biolegend), anti- mouse IgG1-BV510 (1:800, Biolegend), single-domain anti-ALFA-Alexa Fluor 647 (1:1000, NanoTag Biotechnologies); anti-mouse IgK-BV786 (1:750, Biolegend), anti-mouse IgM-BV421 (1:100, Biolegend), anti-mouse IgA-PE (1:1500, eBioscience), anti-mouse IgD-BV711 (1:800, Biolegend); polyclonal anti-human LILRB1-Alexa Fluor 647 (1:800, R&D Systems, conjugated with Alexa fluor 647 conjugation kit, Abcam); anti-mouse B220-BV786 (1:1250, Biolegend), anti-mouse IgM-BV421 (1:100, Biolegend), anti-mouse IgG1-BV510 (1:800, Biolegend), anti-mouse IgD-BV711 (1:800, Biolegend), anti-mouse IgA-PE (1:1500, eBioscience), single-domain anti-ALFA-Alexa Fluor 647 (1:1000, NanoTag Biotechnologies); DAPI (1:4000, Biolegend), anti-mouse IgK-FITC (1:1000, Biolegend), anti-mouse IgM- PE (Biolegend), and single-domain anti-ALFA-Alexa Fluor 647 (1:1000, NanoTag Biotechnologies). Transfected Expi293T cells were stained with DAPI (1:4000, Biolegend), anti-mouse IgK-FITC (1:1000, Biolegend), human CD3-PE-Cy7 (1:1800, Acro Biosystems, conjugated with PE-Cy7 conjugation kit, Abcam), anti-mouse IgM-BV421 (1:100, Biolegend), and single- domain anti-ALFA-Alexa Fluor 647 (1:1000, NanoTag Biotechnologies) or polyclonal anti- human LILRB1-Alexa Fluor 647 (1:800, R&D Systems). Anti-mouse IgG1-BV510 (1:800, Biolegend) and anti-mouse IgA-PE (1:1500, eBioscience) were also used in some staining experiments. Wash buffer during staining was DPBS (Ca2+, Mg2+free) containing 2 mM EDTA and 0.5% bovine serum albumin (BSA). Stained cells were analyzed with the Cytek® Aurora system or sorted with the BD FACSAria™ system. PCR and Sanger sequencing Genomic DNA was isolated with Nucleospin® Tissue or Nucleospin® Tissue XS kit (Takara). Nested PCR was performed using PrimeSTAR® GXL Polymerase kit (Takara). PCR UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ products were run on 0.8-1% agarose gel, excised, and purified with Nucleospin® Gel and PCR Clean-up kit (Takara). In Sanger sequencing experiments, PCR products were cloned into pNL1.2 plasmid (Promega) at the HindIII site using In-Fusion cloning kit (Takara). Stable competent E. coli (NEB) were transformed with the cloned plasmids, streaked on agar plates and grown for twenty-four hours at 30oC. Plates were submitted to Genewiz for Sanger sequencing of bacterial colonies. Analysis Software Data were analyzed and graphed using GraphPad Prism 9. Flow cytometry data were analyzed and plotted using FlowJo 10. Sequences were aligned using SnapGene version 4.3.11 and BLAST. Figures and schematics were assembled on Adobe Ilustrator. INCORPORATION BY REFERENCE The present application refers to various issued patent, published patent applications, scientific journal articles, and other publications, all of which are incorporated herein by reference. The details of one or more embodiments of the invention are set forth herein. Other features, objects, and advantages of the invention will be apparent from the Detailed Description, the Figures, the Examples, and the Claims. EQUIVALENTS While several inventive embodiments have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and / or structures for performing the function and / or obtaining the results and / or one or more of the advantages described herein, and each of such variations and / or modifications is deemed to be within the scope of the inventive embodiments described herein. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and / or configurations will depend upon the specific application or applications for which the inventive teachings is / are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific inventive embodiments UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and / or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and / or methods, if such features, systems, articles, materials, kits, and / or methods are not mutually inconsistent, is included within the inventive scope of the present disclosure. All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms. All references, patents and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may encompass the entirety of the document. The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.” The phrase “and / or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and / or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and / or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and / or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc. As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and / or” as defined above. For example, when separating items in a list, “or” or “and / or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law. As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and / or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc. It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited. In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” “composed of,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03. It should be appreciated that embodiments described in this document using an open-ended transitional phrase (e.g., “comprising”) are also contemplated, in alternative embodiments, as “consisting of” and “consisting essentially of” the UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ feature described by the open-ended transitional phrase. For example, if the disclosure describes “a composition comprising A and B”, the disclosure also contemplates the alternative embodiments “a composition consisting of A and B” and “a composition consisting essentially of A and B”.
Claims
UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ CLAIMS What is claimed is:
1. A nucleic acid comprising from 5' to 3' a first homology arm, a heterologous nucleic acid, and a second homology arm, wherein at least one of the homology arms comprises homology to: a sequence within an active immunoglobulin switch (S) region; a sequence proximal to an active immunoglobulin switch (S) region; or a sequence spanning the boundary of an active immunoglobulin switch (S) region and a sequence proximal to the active immunoglobulin S region.
2. The nucleic acid of claim 1, wherein the sequence proximal to the active immunoglobulin S region comprises a human immunoglobulin heavy chain locus sequence or a mouse immunoglobulin heavy chain locus sequence.
3. The nucleic acid of claim 2, wherein the human immunoglobulin heavy chain locus sequence comprises sequences in one or more of the human VDJ exons, human E^ enhancer, human I^ intron, human S^ region, human Cµ exon, human C^ exon, human I^3 intron, human S^3 region, human C^3 exon, human I^1 intron, human S^1 region, human C^1 exon, human I^1 intron, human S^1region, human C^1exon, human ^13’ regulatory region (3’ RR), I^2intron, human S^2region, human C^2exon, human I^4intron, human S^4region, human C^4exon, human I^ intron, human S^ region, human C^ exon, human I^2 intron, human S^2 region, C^2 exon,,^23’ regulatory region (3’ RR), or an intervening genomic sequence thereof, optionally wherein the human immunoglobulin heavy chain locus sequence comprises sequences located in the first J segment of human VDJ, the human C^2 exon, and / or any intervening sequence between the first J segment of human VDJ and the human C^2 exon thereof.
4. The nucleic acid of claim 2, wherein the mouse immunoglobulin heavy chain sequence comprises sequences in one or more of the mouse VDJ exons, mouse E^ enhancer, mouse I^ intron, mouse S^ region, mouse C^ exon, mouse C^ exon, mouse I^3intron, mouse S^3region, mouse C^3 exon, mouse I^1 intron, mouse S^1 region, mouse C^1 exon, mouse I^2b intron, mouse S^2b region, mouse C^2b exon, mouse I^2^ intron, mouse S^2^ region, mouse C^2^ exon, mouse I^UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ intron, mouse S^ region, mouse C^ exon, mouse I^ intron, mouse S^ region, mouse C^ exon, mouse 3’ regulatory region (3’ RR), or an intervening genome sequence thereof, optionally wherein the mouse immunoglobulin heavy chain locus sequence comprises sequences located in the first J segment of mouse VDJ, the mouse C^ exon, and / or any intervening sequence between the first J segment of mouse VDJ and the mouse C^ exon thereof.
5. The nucleic acid of any one of claims 1-4, wherein the sequence proximal to the active immunoglobulin S region is upstream of the active immunoglobulin S region.
6. The nucleic acid of claim 5, wherein the sequence proximal to the active immunoglobulin S region is 1-1000 nucleotides upstream of the active immunoglobulin S region.
7. The nucleic acid of any one of claims 1-4, wherein the sequence proximal to the active immunoglobulin S region is downstream of the active immunogloblin S region.
8. The nucleic acid of claim 7, wherein the sequence proximal to the active immunoglobulin S region is 1-1000 nucleotides downstream of the active immunoglobulin S region.
9. The nucleic acid of any one of claims 1-3 or 5-8, wherein the active immunoglobulin S region comprises a human S^ region, a human S^3 region, a human S^1 region, a human S^1 region, a human S^2 region, a human S^4 region, or a human S^ region.
10. The nucleic acid of any one of claims 1-2 or 4-8, wherein the active immunoglobulin S region comprises a mouse S^ region, a mouse S^3 region, a mouse S^1 region, a mouse S^2b region, a mouse S^2^region, a mouse S^ region, or a mouse S^ region.
11. The nucleic acid of any one of claims 1-10, wherein the homology arms comprise 20- 2000 nucleotides in length.
12. The nucleic acid of any one of claims 1-11, wherein only one of the homology arms comprises homology to the sequence proximal to the active immunoglobulin S region.UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ 13. The nucleic acid of any one of claims 1-12, wherein only one of the homology arms comprises homology to a sequence proximal to the active immunoglobulin S region and the other homology arm comprises homology to sequences within the same active immunoglobulin S region or a different active S region.
14. The nucleic acid of any one of claims 1-11, wherein both homology arms comprise homology to sequences proximal to the same active immunoglobulin S region, wherein one homology arm comprises homology to a sequence upstream and proximal to the active immunoglobulin S region and the other homology arm comprises homology to a sequence downstream and proximal to the active immunoglobulin S region.
15. The nucleic acid of claim 14, wherein one homology arm comprises homology to a sequence 1-1000 nucleotides upstream of the active immunoglobulin S region and the other homology arm comprises homology to a sequence 1-1000 nucleotides downstream of the active immunoglobulin S region.
16. The nucleic acid of any one of claims 1-11, wherein at least one homology arm comprises homology to a sequence within the active immunoglobulin S region.
17. The nucleic acid of any one of claims 1-11, wherein both homology arms comprise homology to a sequence within the same active immunoglobulin S region or different active immunoglobulin S regions.
18. The nucleic acid of any one of claims 1-17, wherein one of the homology arms comprises homology to sequences upstream of at least one AID target motif in the active S region, and the other homology arm comprises homology to sequences downstream of at least one AID target motif in the same active immunoglobulin S region.
19. The nucleic acid of any one of claims 1-17, wherein one homology arm comprises homology to sequences upstream of an AID target motif in a first active immunoglobulin SUF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ region and the other homology comprises homology to sequences downstream of an AID target motif in a second active immunoglobulin S region, wherein the first active immunoglobulin S region is upstream of the second active immunoglobulin S region.
20. The nucleic acid of any one of claims 1-19, wherein the heterologous nucleic acid comprises 1-3000 nucleotides in length.
21. The nucleic acid of any one of claims 1-20, wherein the heterologous nucleic acid comprises a nucleic acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to any one of the nucleotide sequences set forth in Tables 3 and 5 or a reverse complement thereof.
22. The nucleic acid of any one of claims 1-20, wherein the heterologous nucleic acid comprises any one of the nucleic acid sequences set forth in Tables 3 and 5.
23. The nucleic acid of any one of claims 1-22, wherein the first homology arm comprises a nucleic acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to any one of the nucleotide sequences set forth in Tables 1-4 or a reverse complement thereof.
24. The nucleic acid of any one of claims 1-22, wherein the first homology arm comprises any one of the nucleic acid sequences set forth in Table 4.
25. The nucleic acid of any one of claims 1-24, wherein the second homology arm comprises a nucleic acid sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to any one of the nucleotide sequences set forth in Tables 1- 4 or reverse complement thereof.
26. The nucleic acid of any one of claims 1-24, wherein the second homology arm comprises any one of the nucleic acid sequences set forth in Table 4.UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ 27. The nucleic acid of any one of claims 1-20, wherein the nucleic acid comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to any one of the nucleotide sequences set forth in Tables 1-6 or a reverse comeplement thereof.
28. The nucleic acid of any one of claims 1-20, wherein the nucleic acid comprises any one of the nucleotide sequences set forth in Tables 3-6.
29. The nucleic acid of any one of claims 1-28, wherein the nucleic acid comprises at least one regulatory sequence.
30. The nucleic acid of claim 29, wherein the at least one regulatory sequence comprises a promoter, an enhancer, or both.
31. The nucleic acid of any one of claims 1-30, wherein the nucleic acid is a vector.
32. The nucleic acid of any one of claims 1-31, further comprising a first adeno-associated virus (AAV) inverted terminal repeat (ITR) located 5' of the first homology arm and a second AAV ITR located 3' of the second homology arm.
33. A recombinant adeno-associated virus (rAAV) particle comprising the nucleic acid of claim 32 and at least one AAV capsid protein.
34. The rAAV particle of claim 33, wherein the at least one capsid protein is of serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV-DJ, or AAV-DJ / 8.
35. A cell comprising the nucleic acid of any one of claims 1-32.
36. The cell of claim 35, wherein the cell is a mammalian cell.
37. The cell of claim 36, wherein the cell is a human cell or a mouse cell.UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ 38. The cell of any one of claims 35-37, wherein the cell is a B cell.
39. The of claim 38, wherein the B cell is a murine lymphoma B-cell.
40. The cell of claim 39, wherein the murine lymphoma B-cell is derived from the CH12-F3 cell line.
41. A cell population comprising a plurality of the cell of any one of claims 35-40.
42. A composition comprising the nucleic acid of any one of claims 1-32, the rAAV particle of claim 33 or 34, the cell of any one of claims 35-40, the cell population of claim 41, or any combination thereof.
43. A pharmaceutical composition comprising the nucleic acid of any one of claims 1-32, the rAAV particle of claim 33 or 34, the cell of any one of claims 35-40, the cell population of claim 41, or any combination thereof.
44. A method comprising contacting one or more cells with the nucleic acid of any one of claims 1-32 or the rAAV particle of claim 33 or 34.
45. The method of claim 44, wherein the cell is a B cell.
46. The method of claim 45, wherein the B cell is a human B cell or a mouse B cell.
47. The method of claim 45 or 46, further comprising contacting the one or more B cells with one or more agents that stimulate CSR.
48. The method of claim 47, wherein the one or more agents comprise one or more of anti- CD40, TGF-^1, IL-4, bacterial lipopolysaccharide (LPS), or anti-CD180.UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ 49. The method of any one of claims 44-48, further comprising transfecting or electroporating the one or more cells before, during, or after being contacted with the nucleic acid and / or the one or more agents that stimulate CSR.
50. The method of any one of claims 44-49, wherein the method further comprises sorting the one or more cells before, during, or after being contacted with the nucleic acid, the rAAV particle, and / or the one or more agents that stimulate CSR.
51. The method of claim 50, wherein sorting the one or more cells comprises subjecting the cells to flow cytometry, optionally wherein flow cytometry comprises fluorescent-activated cell sorting (FACS).
52. The method of any one of claims any one of 44-51, wherein the method does not comprise contacting the one or more cells with an exogenous nuclease.
53. The method of any one of claims 44-52, further comprising administering the one or more cells to a subject.
54. A genetically modified B cell produced by the method of any one of claims 45-52.
55. A cell population comprising a plurality of the genetically modified B according to claim 54.
56. An engineered immunoglobulin produced or obtained from the genetically modified B cell of claim 54 or the cell population of claim 55.
57. The engineered immunoglobulin of claim 56, wherein the engineered immunoglobulin is an engineered variant of human IgM, human IgD, human IgG3, human IgG1, human IgA1, human IgG2, human IgG4, human IgE, or human IgA2.UF Ref. No.: S-T00357WO001 WGS Ref. No.: U1197.70221WO00 ^ 58. The engineered immunoglobulin of claim 56, wherein the engineered immunoglobulin is an engineered variant of mouse IgM, mouse IgD, mouse IgG3, mouse IgG1, mouse IgG2b, mouse IgG2a, mouse IgE, or mouse IgA.
59. A composition comprising the genetically modified B cell of claim 54, the cell population of claim 55, or the engineered immunoglobulin of any one of claims 56-58.
60. A pharmaceutical composition comprising the genetically modified B cell of claim 54, the cell population of claim 55, or the engineered immunoglobulin of any one of claims 56-58.
61. A kit comprising the nucleic acid of any one of claims 1-32, the rAAV particle of claim 33 or 34, the genetically modified B cell of claim 54, the cell population of claim 55, or the engineered immunoglobulin of any one of claims 56-58.
62. The kit of claim 61, wherein the kit further comprises instructions to perform the method of any one of claims 44-53.
63. A method of treating a subject in need thereof, the comprising administering to the subject the nucleic acid of any one of claims 1-32, the rAAV particle of claim 33 or 34, the genetically modified B cell of claim 54, the cell population of claim 55, or the engineered immunoglobulin of any one of claims 56-58.
64. The method of claim 63, wherein the subject has, is suspected of having, or at risk of developing a disease or disorder selected from the group consisting of cancer, an autoimmune disease, or an infection with a pathogen. ^
Citation Information
Patent Citations
Immunoglobulin class switch recombination
US20030059763A1
Genetic engneering of b cell receptors and uses thereof in antigen-induced antibody secretion
US20210269771A1
